Receptors, Antigen: Molecules on the surface of B- and T-lymphocytes that recognize and combine with specific antigens.Hematopoietic Stem Cells: Progenitor cells from which all blood cells derive.Lymphoma, T-Cell, Cutaneous: A group of lymphomas exhibiting clonal expansion of malignant T-lymphocytes arrested at varying stages of differentiation as well as malignant infiltration of the skin. MYCOSIS FUNGOIDES; SEZARY SYNDROME; LYMPHOMATOID PAPULOSIS; and PRIMARY CUTANEOUS ANAPLASTIC LARGE CELL LYMPHOMA are the best characterized of these disorders.Antigens, CD19: Differentiation antigens expressed on B-lymphocytes and B-cell precursors. They are involved in regulation of B-cell proliferation.Cell Line, Tumor: A cell line derived from cultured tumor cells.Antigens, CD3: Complex of at least five membrane-bound polypeptides in mature T-lymphocytes that are non-covalently associated with one another and with the T-cell receptor (RECEPTORS, ANTIGEN, T-CELL). The CD3 complex includes the gamma, delta, epsilon, zeta, and eta chains (subunits). When antigen binds to the T-cell receptor, the CD3 complex transduces the activating signals to the cytoplasm of the T-cell. The CD3 gamma and delta chains (subunits) are separate from and not related to the gamma/delta chains of the T-cell receptor (RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA).Hematopoietic Stem Cell Transplantation: Transfer of HEMATOPOIETIC STEM CELLS from BONE MARROW or BLOOD between individuals within the same species (TRANSPLANTATION, HOMOLOGOUS) or transfer within the same individual (TRANSPLANTATION, AUTOLOGOUS). Hematopoietic stem cell transplantation has been used as an alternative to BONE MARROW TRANSPLANTATION in the treatment of a variety of neoplasms.Antigens, CD8: Differentiation antigens found on thymocytes and on cytotoxic and suppressor T-lymphocytes. CD8 antigens are members of the immunoglobulin supergene family and are associative recognition elements in MHC (Major Histocompatibility Complex) Class I-restricted interactions.Antigens, CD34: Glycoproteins found on immature hematopoietic cells and endothelial cells. They are the only molecules to date whose expression within the blood system is restricted to a small number of progenitor cells in the bone marrow.Antigens, CD28: Costimulatory T-LYMPHOCYTE receptors that have specificity for CD80 ANTIGEN and CD86 ANTIGEN. Activation of this receptor results in increased T-cell proliferation, cytokine production and promotion of T-cell survival.Lymphoma, Large-Cell, Anaplastic: A systemic, large-cell, non-Hodgkin, malignant lymphoma characterized by cells with pleomorphic appearance and expressing the CD30 ANTIGEN. These so-called "hallmark" cells have lobulated and indented nuclei. This lymphoma is often mistaken for metastatic carcinoma and MALIGNANT HISTIOCYTOSIS.Hodgkin Disease: A malignant disease characterized by progressive enlargement of the lymph nodes, spleen, and general lymphoid tissue. In the classical variant, giant usually multinucleate Hodgkin's and REED-STERNBERG CELLS are present; in the nodular lymphocyte predominant variant, lymphocytic and histiocytic cells are seen.Antigens, CD30: A member of the tumor necrosis factor receptor superfamily that may play a role in the regulation of NF-KAPPA B and APOPTOSIS. They are found on activated T-LYMPHOCYTES; B-LYMPHOCYTES; NEUTROPHILS; EOSINOPHILS; MAST CELLS and NK CELLS. Overexpression of CD30 antigen in hematopoietic malignancies make the antigen clinically useful as a biological tumor marker. Signaling of the receptor occurs through its association with TNF RECEPTOR-ASSOCIATED FACTORS.Lymphoma, Large B-Cell, Diffuse: Malignant lymphoma composed of large B lymphoid cells whose nuclear size can exceed normal macrophage nuclei, or more than twice the size of a normal lymphocyte. The pattern is predominantly diffuse. Most of these lymphomas represent the malignant counterpart of B-lymphocytes at midstage in the process of differentiation.Lymphoma: A general term for various neoplastic diseases of the lymphoid tissue.Lymphoma, T-Cell: A group of heterogeneous lymphoid tumors representing malignant transformations of T-lymphocytes.Lymphoma, Non-Hodgkin: Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.Lymphoma, B-Cell: A group of heterogeneous lymphoid tumors generally expressing one or more B-cell antigens or representing malignant transformations of B-lymphocytes.Antigens: Substances that are recognized by the immune system and induce an immune reaction.Lymphomatoid Papulosis: Clinically benign, histologically malignant, recurrent cutaneous T-cell lymphoproliferative disorder characterized by an infiltration of large atypical cells surrounded by inflammatory cells. The atypical cells resemble REED-STERNBERG CELLS of HODGKIN DISEASE or the malignant cells of CUTANEOUS T-CELL LYMPHOMA. In some cases, lymphomatoid papulosis progresses to lymphomatous conditions including MYCOSIS FUNGOIDES; HODGKIN DISEASE; CUTANEOUS T-CELL LYMPHOMA; or ANAPLASTIC LARGE-CELL LYMPHOMA.Research Support, U.S. Gov't, Non-P.H.S.Research Support, U.S. Gov't, P.H.S.Research Support, Non-U.S. Gov'tResearch Support, U.S. GovernmentResearch Support, American Recovery and Reinvestment ActResearch Support, N.I.H., ExtramuralResearch Support, N.I.H., IntramuralResearch Support as Topic: Financial support of research activities.Maximum Tolerated Dose: The highest dose of a biologically active agent given during a chronic study that will not reduce longevity from effects other than carcinogenicity. (from Lewis Dictionary of Toxicology, 1st ed)Treatment Outcome: Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.Disease Progression: The worsening of a disease over time. This concept is most often used for chronic and incurable diseases where the stage of the disease is an important determinant of therapy and prognosis.Dose-Response Relationship, Drug: The relationship between the dose of an administered drug and the response of the organism to the drug.Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.Receptors, Tumor Necrosis Factor: Cell surface receptors that bind TUMOR NECROSIS FACTORS and trigger changes which influence the behavior of cells.Fushi Tarazu Transcription Factors: Fushi tarazu transcription factors were originally identified in DROSOPHILA. They are found throughout ARTHROPODS and play important roles in segmentation and CENTRAL NERVOUS SYSTEM development.Search Engine: Software used to locate data or information stored in machine-readable form locally or at a distance such as an INTERNET site.Databases, Genetic: Databases devoted to knowledge about specific genes and gene products.Genome, Human: The complete genetic complement contained in the DNA of a set of CHROMOSOMES in a HUMAN. The length of the human genome is about 3 billion base pairs.TNF Receptor-Associated Factor 1: A signal transducing tumor necrosis factor receptor associated factor that is involved in TNF RECEPTOR feedback regulation. It is similar in structure and appears to work in conjunction with TNF RECEPTOR-ASSOCIATED FACTOR 2 to inhibit APOPTOSIS.Tumor Necrosis Factors: A family of proteins that were originally identified by their ability to cause NECROSIS of NEOPLASMS. Their necrotic effect on cells is mediated through TUMOR NECROSIS FACTOR RECEPTORS which induce APOPTOSIS.Antibodies: Immunoglobulin molecules having a specific amino acid sequence by virtue of which they interact only with the ANTIGEN (or a very similar shape) that induced their synthesis in cells of the lymphoid series (especially PLASMA CELLS).Internet: A loose confederation of computer communication networks around the world. The networks that make up the Internet are connected through several backbone networks. The Internet grew out of the US Government ARPAnet project and was designed to facilitate information exchange.Receptors, Tumor Necrosis Factor, Type I: A tumor necrosis factor receptor subtype that has specificity for TUMOR NECROSIS FACTOR ALPHA and LYMPHOTOXIN ALPHA. It is constitutively expressed in most tissues and is a key mediator of tumor necrosis factor signaling in the vast majority of cells. The activated receptor signals via a conserved death domain that associates with specific TNF RECEPTOR-ASSOCIATED FACTORS in the CYTOPLASM.Immunoconjugates: Combinations of diagnostic or therapeutic substances linked with specific immune substances such as IMMUNOGLOBULINS; MONOCLONAL ANTIBODIES; or ANTIGENS. Often the diagnostic or therapeutic substance is a radionuclide. These conjugates are useful tools for specific targeting of DRUGS and RADIOISOTOPES in the CHEMOTHERAPY and RADIOIMMUNOTHERAPY of certain cancers.Cardiotoxins: Agents that have a damaging effect on the HEART. Such damage can occur from ALKYLATING AGENTS; FREE RADICALS; or metabolites from OXIDATIVE STRESS and in some cases is countered by CARDIOTONIC AGENTS. Induction of LONG QT SYNDROME or TORSADES DE POINTES has been the reason for viewing some drugs as cardiotoxins.Lymphoma, Primary Effusion: A rare neoplasm of large B-cells usually presenting as serious effusions without detectable tumor masses. The most common sites of involvement are the pleural, pericardial, and peritoneal cavities. It is associated with HUMAN HERPESVIRUS 8, most often occurring in the setting of immunodeficiency.Double-Blind Method: A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment.Antineoplastic Agents: Substances that inhibit or prevent the proliferation of NEOPLASMS.National Cancer Institute (U.S.): Component of the NATIONAL INSTITUTES OF HEALTH. Through basic and clinical biomedical research and training, it conducts and supports research with the objective of cancer prevention, early stage identification and elimination. This Institute was established in 1937.Antibodies, Monoclonal: Antibodies produced by a single clone of cells.CHO Cells: CELL LINE derived from the ovary of the Chinese hamster, Cricetulus griseus (CRICETULUS). The species is a favorite for cytogenetic studies because of its small chromosome number. The cell line has provided model systems for the study of genetic alterations in cultured mammalian cells.Muromonab-CD3: Anti-CD3 monoclonal antibody that exerts immunosuppressive effects by inducing peripheral T-cell depletion and modulation of the T-cell receptor complex (CD3/Ti).Cell Line: Established cell cultures that have the potential to propagate indefinitely.Transfection: The uptake of naked or purified DNA by CELLS, usually meaning the process as it occurs in eukaryotic cells. It is analogous to bacterial transformation (TRANSFORMATION, BACTERIAL) and both are routinely employed in GENE TRANSFER TECHNIQUES.Smegma: A foul-smelling accumulation of SEBUM and desquaminated epidermal cells, especially the cheesy substance found under the foreskin of the penis and at the base of the labia minor near the clitoris.Cricetinae: A subfamily in the family MURIDAE, comprising the hamsters. Four of the more common genera are Cricetus, CRICETULUS; MESOCRICETUS; and PHODOPUS.Antigens, CD: Differentiation antigens residing on mammalian leukocytes. CD stands for cluster of differentiation, which refers to groups of monoclonal antibodies that show similar reactivity with certain subpopulations of antigens of a particular lineage or differentiation stage. The subpopulations of antigens are also known by the same CD designation.Psoriasis: A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches. The lesions have a predilection for nails, scalp, genitalia, extensor surfaces, and the lumbosacral region. Accelerated epidermopoiesis is considered to be the fundamental pathologic feature in psoriasis.Cyclosporine: A cyclic undecapeptide from an extract of soil fungi. It is a powerful immunosupressant with a specific action on T-lymphocytes. It is used for the prophylaxis of graft rejection in organ and tissue transplantation. (From Martindale, The Extra Pharmacopoeia, 30th ed).Mycosis Fungoides: A chronic, malignant T-cell lymphoma of the skin. In the late stages, the LYMPH NODES and viscera are affected.Lymphoma, Primary Cutaneous Anaplastic Large Cell: Anaplastic lymphoma of the skin which develops as a primary neoplasm expressing the CD30 ANTIGEN. It is characterized by solitary nodules or ulcerated tumors.Receptor Protein-Tyrosine Kinases: A class of cellular receptors that have an intrinsic PROTEIN-TYROSINE KINASE activity.Chromosomes, Human, Pair 2: A specific pair of human chromosomes in group A (CHROMOSOMES, HUMAN, 1-3) of the human chromosome classification.Herpesvirus 4, Human: The type species of LYMPHOCRYPTOVIRUS, subfamily GAMMAHERPESVIRINAE, infecting B-cells in humans. It is thought to be the causative agent of INFECTIOUS MONONUCLEOSIS and is strongly associated with oral hairy leukoplakia (LEUKOPLAKIA, HAIRY;), BURKITT LYMPHOMA; and other malignancies.Epstein-Barr Virus Infections: Infection with human herpesvirus 4 (HERPESVIRUS 4, HUMAN); which may facilitate the development of various lymphoproliferative disorders. These include BURKITT LYMPHOMA (African type), INFECTIOUS MONONUCLEOSIS, and oral hairy leukoplakia (LEUKOPLAKIA, HAIRY).Epstein-Barr Virus Nuclear Antigens: Nuclear antigens encoded by VIRAL GENES found in HUMAN HERPESVIRUS 4. At least six nuclear antigens have been identified.Stomach Neoplasms: Tumors or cancer of the STOMACH.Cell Nucleus: Within a eukaryotic cell, a membrane-limited body which contains chromosomes and one or more nucleoli (CELL NUCLEOLUS). The nuclear membrane consists of a double unit-type membrane which is perforated by a number of pores; the outermost membrane is continuous with the ENDOPLASMIC RETICULUM. A cell may contain more than one nucleus. (From Singleton & Sainsbury, Dictionary of Microbiology and Molecular Biology, 2d ed)Carcinoma: A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm but is often wrongly used as a synonym for "cancer." (From Dorland, 27th ed)Immunohistochemistry: Histochemical localization of immunoreactive substances using labeled antibodies as reagents.Polymerase Chain Reaction: In vitro method for producing large amounts of specific DNA or RNA fragments of defined length and sequence from small amounts of short oligonucleotide flanking sequences (primers). The essential steps include thermal denaturation of the double-stranded target molecules, annealing of the primers to their complementary sequences, and extension of the annealed primers by enzymatic synthesis with DNA polymerase. The reaction is efficient, specific, and extremely sensitive. Uses for the reaction include disease diagnosis, detection of difficult-to-isolate pathogens, mutation analysis, genetic testing, DNA sequencing, and analyzing evolutionary relationships.Viral Matrix Proteins: Proteins associated with the inner surface of the lipid bilayer of the viral envelope. These proteins have been implicated in control of viral transcription and may possibly serve as the "glue" that binds the nucleocapsid to the appropriate membrane site during viral budding from the host cell.

Plasma-soluble CD30 in childhood tuberculosis: effects of disease severity, nutritional status, and vitamin A therapy. (1/479)

Plasma-soluble CD30 (sCD30) is the result of proteolytic splicing from the membrane-bound form of CD30, a putative marker of type 2 cytokine-producing cells. We measured sCD30 levels in children with tuberculosis, a disease characterized by prominent type 1 lymphocyte cytokine responses. We postulated that disease severity and nutritional status would alter cytokine responses and therefore sCD30 levels. Samples from South African children enrolled prospectively at the time of diagnosis of tuberculosis were analyzed. (Patients were originally enrolled in a randomized, double-blind placebo-controlled study of the effects of oral vitamin A supplementation on prognosis of tuberculosis.) Plasma samples collected at the time of diagnosis and 6 and 12 weeks later (during antituberculosis therapy) were analyzed. sCD30 levels were measured by enzyme immunoassay. The 91 children included in the study demonstrated high levels of sCD30 at diagnosis (median, 98 U/liter; range, 11 to 1,569 U/liter). Although there was a trend toward higher sCD30 levels in more severe disease (e.g., culture-positive disease or miliary disease), this was not statistically significant. Significantly higher sCD30 levels were demonstrated in the presence of nutritional compromise: the sCD30 level was higher in patients with a weight below the third percentile for age, in those with clinical signs of kwashiorkor, and in those with a low hemoglobin content. There was minimal change in the sCD30 level after 12 weeks of therapy, even though patients improved clinically. However, changes in sCD30 after 12 weeks differed significantly when 46 patients (51%) who received vitamin A were compared with those who had received a placebo. Vitamin A-supplemented children demonstrated a mean (+/- standard error of the mean) decrease in sCD30 by a factor of 0.99 +/- 0.02 over 12 weeks, whereas a factor increase of 1.05 +/- 0.02 was demonstrated in the placebo group (P = 0.02). We conclude that children with tuberculosis had high sCD30 levels, which may reflect the presence of a type 2 cytokine response. Nutritional compromise was associated with higher sCD30 levels. Vitamin A therapy resulted in modulation of sCD30 levels over time.  (+info)

Autologous stem cell transplantation for T and null cell CD30-positive anaplastic large cell lymphoma: analysis of 64 adult and paediatric cases reported to the European Group for Blood and Marrow Transplantation (EBMT). (2/479)

Anaplastic large cell lymphoma (ALCL) is a heterogeneous family of lymphoid tumours, among which the T and null cell types were recently listed in the REAL classification as a distinct entity. Reports on autologous stem cell transplantation (ASCT) in this group are only occasional. Sixty-four patients with T and null cell ALCL from 25 European centres had been registered with the European Group for Blood and Marrow Transplantation (EBMT) at the onset of this study. The median age was 25 years (range 3.2-53.0). Thirty of the 64 patients (47%) were in complete remission (CR), 18 (28%) in partial remission (PR), and the remaining 16 (25%) had a more advanced or chemotherapy-refractory disease at transplant. Eighty-one percent of the patients were conditioned with chemotherapy alone and 75% received marrow stem cells. All the patients transplanted in first CR (15), except one, maintained the CR over time; six of 15 transplanted in CR subsequent to first, six of 18 transplanted in PR and 14 of 16 transplanted in refractory or relapsed disease progressed. Actuarial overall survival (OS) at 10 years is 70%. Multivariate analysis showed that good status at transplant, younger age, absence of B symptoms and absence of extranodal disease indicated a better prognosis. These data suggest that ASCT should be considered as a possible treatment for chemosensitive patients in CR or PR. However, definitive conclusions cannot be drawn from this study and a prospective randomised trial between ASCT and conventional chemotherapy may be indicated.  (+info)

ALK+ lymphoma: clinico-pathological findings and outcome. (3/479)

A distinct pathologic entity (ALK+ lymphoma) that is characterized by expression of the anaplastic lymphoma kinase (ALK) protein has recently emerged within the heterogeneous group of CD30(+) anaplastic large-cell lymphomas. Information on clinical findings and treatment outcome of ALK+ lymphoma is still limited, and no data are available concerning the value of the International Prognostic Index when applied to this homogeneous disease entity. To clarify these issues, a recently developed monoclonal antibody ALKc (directed against the cytoplasmic portion of ALK) was used to detect expression of the ALK protein in paraffin-embedded biopsies from 96 primary, systemic T/null anaplastic large-cell lymphomas, and the ALK staining pattern was correlated with morphological features, clinical findings, risk factors (as defined by the International Prognostic Index), and outcome in 78 patients (53 ALK+ and 25 ALK-). Strong cytoplasmic and/or nuclear ALK positivity was detected in 58 of 96 ALCL cases (60.4%), and it was associated with a morphological spectrum (common type, 82.7%; giant cell, 3.5%; lymphohistiocytic, 8. 6%; and small cell, 5.2%) that reflected the ratio of large anaplastic elements (usually showing cytoplasmic and nuclear ALK positivity) to small neoplastic cells (usually characterized by nucleus-restricted ALK expression). Clinically, ALK+ lymphoma mostly occurred in children and young adults (mean age, 22.01 +/- 10.87 years) with a male predominance (male/female [M/F] ratio, 3.0) that was particularly striking in the second-third decades of life (M/F ratio, 6.5) and usually presented as an aggressive, stage III-IV disease, frequently associated with systemic symptoms (75%) and extranodal involvement (60%), especially skin (21%), bone (17%), and soft tissues (17%). As compared with ALK+ lymphoma, ALK- cases occurred in older individuals (mean age, 43.33 +/- 16.15 years) and showed a lower M/F ratio (0.9) as well as lower incidence of stage III-IV disease and extranodal involvement at presentation. Overall survival of ALK+ lymphoma was far better than that of ALK- anaplastic large-cell lymphoma (71% +/- 6% v 15% +/- 11%, respectively). However, within the good prognostic category of ALK+ lymphoma, survival was 94% +/- 5% for the low/low intermediate risk group (age-adjusted International Prognostic Index, 0 to 1) and 41% +/- 12% for the high/high intermediate risk group (age-adjusted International Prognostic Index, >/=2). Multivariate analysis identified ALK expression and the International Prognostic Index as independent variables that were able to predict survival among T/null primary, systemic anaplastic large-cell lymphoma. Thus, we suggest that such parameters should be taken into consideration for the design of future clinical trials.  (+info)

The T-cell activation markers CD30 and OX40/CD134 are expressed in nonoverlapping subsets of peripheral T-cell lymphoma. (4/479)

The tumor necrosis factor (TNF) receptor family includes several important markers of activation in T cells. We examined expression patterns of two T-cell-associated members of these receptors, namely CD30 and OX40/CD134, in 148 cases of T-cell lymphoma to identify possible objective immunohistochemical criteria for subclassification of these tumors. CD30 expression was characteristic of tumors with an anaplastic (46/47 cases [98%]) or large-cell (10/21 [48%]) morphology and was seen in only scattered cells in other tumor types. In contrast, large numbers of OX40/CD134(+) tumors cells were typical of angioimmunoblastic lymphoma (15/16 [94%]), angiocentric lymphoma (4/4), a subset of large-cell lymphomas (10/21 [48%]), and lymphomas with a prominent histiocytic component (6/7 [86%]). Strong OX40/CD134 and CD30 coexpression was seen in only 4% of tumors, typically those with an anaplastic/Hodgkin's-like appearance. OX40/CD134 expression was characteristic of tumors composed of activated CD4(+) T cells and was not seen in small-cell T-cell lymphomas, lymphoblastic lymphomas, or other tumor types, including B-cell lymphomas or carcinomas. These results suggest that immunostaining for OX40/CD134 may be helpful in subclassification of peripheral T-cell lymphomas and that the patterns of TNF receptor family expression in these tumors may parallel those seen within nonneoplastic helper T-cell subsets.  (+info)

Induction of cell death by tumour necrosis factor (TNF) receptor 2, CD40 and CD30: a role for TNF-R1 activation by endogenous membrane-anchored TNF. (5/479)

Several members of the tumour necrosis factor receptor (TNF-R) superfamily can induce cell death. For TNF-R1, Fas/APO-1, DR3, DR6, TRAIL-R1 and TRAIL-R2, a conserved 'death domain' in the intracellular region couples these receptors to activation of caspases. However, it is not yet known how TNF receptor family members lacking a death domain, such as TNF-R2, CD40, LT-betaR, CD27 or CD30, execute their death-inducing capability. Here we demonstrate in different cellular systems that cytotoxic effects induced by TNF-R2, CD40 and CD30 are mediated by endogenous production of TNF and autotropic or paratropic activation of TNF-R1. In addition, stimulation of TNF-R2 and CD40 synergistically enhances TNF-R1-induced cytotoxicity. These findings describe a novel pro-apoptotic mechanism induced by some members of the TNF-R family.  (+info)

An anti-CD30 single-chain Fv selected by phage display and fused to Pseudomonas exotoxin A (Ki-4(scFv)-ETA') is a potent immunotoxin against a Hodgkin-derived cell line. (6/479)

The human CD30 receptor is highly overexpressed on the surface of Hodgkin Reed-Sternberg cells and has been shown to be an excellent target for selective immunotherapy using monoclonal antibody-based agents such as immunotoxins. To construct a new recombinant immunotoxin for possible clinical use in patients with Hodgkin's lymphoma, we have chosen the murine anti-CD30 hybridoma Ki-4 to generate a high-affinity Ki-4 single-chain variable fragment (scFv). Hybridoma V-genes were polymerase chain reaction-amplified, assembled, cloned and expressed as a mini-library for display on filamentous phage. Functional Ki-4 scFv were obtained by selection of binding phage on the Hodgkin lymphoma-derived, CD30-expressing cell line L540Cy. The selected recombinant Ki-4 scFv was shown to specifically bind to an overlapping epitope on the CD30 antigen with binding kinetics similar to those of the original antibody. The Ki-4 scFv was subsequently fused to a deletion mutant of Pseudomonas exotoxin A (ETA'). The resulting immunotoxin Ki-4(scFv)-ETA' specifically binds to CD30+ L540Cy cells and inhibits the protein synthesis by 50% at a concentration (IC50) of 43 pM. This recombinant immunotoxin is a promising candidate for further clinical evaluation in patients with Hodgkin's lymphoma or other CD30+ malignancies.  (+info)

CD30 overexpression enhances negative selection in the thymus and mediates programmed cell death via a Bcl-2-sensitive pathway. (7/479)

The biological function of CD30 in the thymus has been only partially elucidated, although recent data indicate that it may be involved in negative selection. Because CD30 is expressed only by a small subpopulation of medullary thymocytes, we generated transgenic (Tg) mice overexpressing CD30 in T lymphocytes to further address its role in T cell development. CD30 Tg mice have normal thymic size with a normal number and subset distribution of thymocytes. In vitro, in the absence of CD30 ligation, thymocytes of CD30 Tg mice have normal survival and responses to apoptotic stimuli such as radiation, dexamethasone, and Fas. However, in contrast to controls, CD30 Tg thymocytes are induced to undergo programmed cell death (PCD) upon cross-linking of CD30, and the simultaneous engagement of TCR and CD30 results in a synergistic increase in thymic PCD. CD30-mediated PCD requires caspase 1 and caspase 3, is not associated with the activation of NF-kappaB or c-Jun, but is totally prevented by Bcl-2. Furthermore, CD30 overexpression enhances the deletion of CD4+/CD8+ thymocytes induced by staphylococcal enterotoxin B superantigen and specific peptide. These findings suggest that CD30 may act as a costimulatory molecule in thymic negative selection.  (+info)

IL-12 receptor beta2 and CD30 expression in paranasal sinus mucosa of patients with chronic sinusitis. (8/479)

The aetiology of chronic sinusitis is still poorly understood. The expression of T-helper 1 (Th1) and T-helper 2 (Th2) cell markers, interleukin (IL)-12 receptor beta2 subunit (IL-12Rbeta2) messenger ribonucleic acid (mRNA) and CD30, respectively, were investigated in the paranasal sinus mucosa of patients with chronic sinusitis in an attempt to elucidate the involvement of Th1 and Th2 cells in this disease. Anterior ethmoidal mucosae were surgically obtained from two groups of patients with chronic sinusitis: those who had allergic rhinitis (allergic group, n=11) and those without allergy (nonallergic group, n=11). IL-12Rbeta2 mRNA was quantified by means of the reverse transcription polymerase chain reaction, and CD30-positive cells were examined immunohistochemically. Both IL-12Rbeta2 mRNA and CD30 were expressed in the sinus mucosa of the allergic and nonallergic groups. The proportion of mononuclear cells which were CD30-positive in the sinus mucosa was significantly greater in the allergic than in the nonallergic group. The expression levels of IL-12Rbeta2 mRNA were virtually equivalent in both groups. These results suggest a T-helper 2-dominated mucosal reaction in the allergic compared to the nonallergic group, and indicate T-helper 1 activity in the sinus mucosa of both groups. The ubiquity of T-helper 1 cells suggests that they play a role in maintaining local mucosal defences against foreign antigens, which continually enter the upper respiratory tract.  (+info)

*Nodular lymphocyte predominant Hodgkin's lymphoma

Unlike classic RSC, the non-classic popcorn-shaped RS cells of NLPHL are CD15 and CD30 negative while positive for the B cell ... and CD79a and also express the common leukocyte antigen CD45, which is uncommon on RSH cells. The LP cells have scant cytoplasm ... RSH cells typically express CD15 and CD30, whereas LP cells lack expression of these markers, but express B cell markers like ...

*HABP4

1992). "Cellular localizations and processing of the two molecular forms of the Hodgkin-associated Ki-1 (CD30) antigen. The ... mapping and partial cDNA sequence of the 57-kD intracellular Ki-1 antigen". Exp Clin Immunogenet. 14 (4): 273-80. PMID 9523163 ...

*Brentuximab vedotin

It selectively targets tumor cells expressing the CD30 antigen, a defining marker of Hodgkin lymphoma and ALCL (a type of T ... The antibody cAC10 part of the drug binds to CD30 which often occurs on diseased cells but rarely on normal tissues.The ... This approval is for patients with primary cutaneous anaplastic large cell lymphoma (pcALCL) and CD30-expressing mycosis ... an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity". Blood. 102 (4): 1458-1465. doi: ...

*List of MeSH codes (D23)

... antigens, cd28 MeSH D23.050.301.264.035.129 --- antigens, cd29 MeSH D23.050.301.264.035.130 --- antigens, cd30 MeSH D23.050. ... antigens, cd28 MeSH D23.101.100.110.129 --- antigens, cd29 MeSH D23.101.100.110.130 --- antigens, cd30 MeSH D23.101.100.110.131 ... forssman antigen MeSH D23.050.285.018 --- antigens, cd24 MeSH D23.050.285.025 --- antigens, cd30 MeSH D23.050.285.040 --- ... antigens, cd30 MeSH D23.101.840.075 --- antigens, tumor-associated, carbohydrate MeSH D23.101.840.075.050 --- antigens, cd15 ...

*CD30

... Antigens at the US National Library of Medicine Medical Subject Headings (MeSH) Human TNFRSF8 genome location and TNFRSF8 ... Josimovic-Alasevic O, Dürkop H, Schwarting R, Backé E, Stein H, Diamantstein T (Jan 1989). "Ki-1 (CD30) antigen is released by ... CD30 and CD15 are also expressed on classical Hodgkin Lymphoma Reed-Sternberg cells. CD30 is the target of the FDA approved ... I. Partial characterization of soluble Ki-1 antigen and detection of the antigen in cell culture supernatants and in serum by ...

*Chemically linked Fab

Typically, one of the Fabs binds to a tumour antigen (such as CD30) and the other to a protein on the surface of an immune cell ... Two chemically linked fragments antigen-binding form an artificial antibody that binds to two different antigens, making it a ... They are fragments antigen-binding (Fab or Fab') of two different monoclonal antibodies and are linked by chemical means like a ... antibody designed for therapy of human B-cell malignancy can induce T-cell activation by antigen-dependent and antigen- ...

*List of MeSH codes (D12.776.543)

... antigens, cd27 MeSH D12.776.543.750.705.852.760.072 -- antigens, cd30 MeSH D12.776.543.750.705.852.760.097 -- antigens, cd40 ... antigen, b-cell MeSH D12.776.543.750.705.816.821.500 -- antigens, cd79 MeSH D12.776.543.750.705.816.824 -- receptors, antigen, ... antigens, cd22 MeSH D12.776.543.550.200.124 -- antigens, cd24 MeSH D12.776.543.550.200.131 -- antigens, cd31 MeSH D12.776. ... antigens, cd11a MeSH D12.776.543.750.705.408.100.150 -- antigens, cd11b MeSH D12.776.543.750.705.408.100.200 -- antigens, cd11c ...

*CD15

It is also called Lewis x and SSEA-1 (stage-specific embryonic antigen 1) and represents a marker for murine pluripotent stem ... Immunohistochemical panels for the diagnosis of Hodgkins disease typically employ CD15 along with CD30 and CD45; the latter ... Sialyl Lewis X CD15 Antigen at the US National Library of Medicine Medical Subject Headings (MeSH) Kerr MA, Stocks SC (November ... CD15 (3-fucosyl-N-acetyl-lactosamine) is a cluster of differentiation antigen - an immunologically significant molecule. CD15 ...

*Immunohistochemistry

... including deparaffinization and antigen retrieval. For formalin-fixed paraffin-embedded tissues, antigen-retrieval is often ... CD15 and CD30 : used for Hodgkin's disease Alpha fetoprotein: for yolk sac tumors and hepatocellular carcinoma CD117 (KIT): for ... Visualising an antibody-antigen interaction can be accomplished in a number of ways. In the most common instance, an antibody ... "IHC Tip 1: Antigen retrieval - should I do PIER or HIER?". AbD Serotec. Pohanka, Miroslav (2009). "Monoclonal and polyclonal ...

*TRG (gene)

The Vδ2+ T cells recognize small nonpeptide antigens, but unlike αβ T cells, these antigens do not need to be processed by ... PMC 4259167 . Gammon B, Gammon BR, Kim YH, Kim J (September 2016). "Neurotropic Gamma-Delta T-Cell Lymphoma With CD30-Positive ... While the αβ lineage has been widely studied, the γδ lineage has not due to the minimal amount of defined antigens, the unusual ... There is a hypothesis that γδ T cells process these pathogenic antigens, transport them to draining lymph nodes, and then ...

*Anaplastic lymphoma kinase

Yaakup H, Sagap I, Fadilah SA (Oct 2008). "Primary oesophageal Ki (CD30)-positive ALK+ anaplastic large cell lymphoma of T-cell ... "ALK as a novel lymphoma-associated tumor antigen: identification of 2 HLA-A2.1-restricted CD8+ T-cell epitopes". Blood. 99 (6 ... CD30(+) lymphoma cells by the Hsp90 antagonist 17-allylamino,17-demethoxygeldanamycin". Cancer Research. 62 (5): 1559-66. PMID ...

*Stem cell marker

CK19, Cytokeratin 19, K19) Kit L-selectin (CD62L) Lamin A/C Lewis X antigen (Le(X)) LeX Lgr5 Lrp4 MCM2 MCSP Metallothionein (MT ... CD30) PECAM-1 (CD31) Siglec-3 (CD33) CD34 CD44 NCAM (CD56) CD73 CD9 CD90 CDCP1 Circulating anticoagulants protein C (PC) CK19 ... May 2006). "Lack of expression of the chondroitin sulphate proteoglycan neuron-glial antigen 2 on candidate stem cell ... Muramatsu T, Muramatsu H (2004). "Carbohydrate antigens expressed on stem cells and early embryonic cells". Glycoconjugate ...

*Interleukin 12

T cells that produce IL-12 have a coreceptor, CD30, which is associated with IL-12 activity. IL-12 plays an important role in ... Interleukin 12 (IL-12) is produced by activated antigen-presenting cells (dendritic cells, macrophages). It promotes the ...

*LAG3

A new ligand for human leukocyte antigen class II antigens". The Journal of Experimental Medicine. 176 (2): 327-37. doi:10.1084 ... "Soluble CD30 and lymphocyte activation gene-3 (CD223), as potential serological markers of T helper-type cytokine response ... A new ligand for human leukocyte antigen class II antigens". The Journal of Experimental Medicine. 176 (2): 327-37. doi:10.1084 ... An initial characterization of the LAG-3 protein was reported in 1992 showing that it was a ligand for MHC class II antigens ...

*Antibody-drug conjugate

The biochemical reaction between the antibody and the target protein (antigen) triggers a signal in the tumor cell, which then ... However, the combination of MMAE linked to an anti-CD30 monoclonal antibody (cAC10, a cell membrane protein of the tumor ... to human specific CD30-positive malignant cells. Because of its high toxicity MMAE, which inhibits cell division by blocking ... "Antibody-Drug Conjugates Designed to Eradicate Tumors with Homogeneous and Heterogeneous Expression of the Target Antigen". ...

*Cancer biomarkers

Examples: Prostate-specific antigen, and CA-125 Tumor marker Calzone, Kathleen A. "Genetic Biomarkers of Cancer Risk". Seminars ... May 2007). "Effective therapy of murine models of human leukemia and lymphoma with radiolabeled anti-CD30 antibody, HeFi-1". ... Bantis, A; Grammaticos, P (Sep-Dec 2012). "Prostatic specific antigen and bone scan in the diagnosis and follow-up of prostate ... Prostate Specific Antigen) (Prostate Cancer), S100 (Melanoma), and many others. Mutant Proteins themselves detected by Selected ...

*Keratin 7

Because the keratin-7 antigen is found in both healthy and neoplastic cells, antibodies to CK7 can be used in ... CD30(+) lymphoma cells by the Hsp90 antagonist 17-allylamino,17-demethoxygeldanamycin". Cancer Research. 62 (5): 1559-66. PMID ...

*List of cutaneous conditions

... system List of spiders associated with cutaneous reactions List of target antigens in pemphigoid List of target antigens in ... non-mycosis fungoides CD30− pleomorphic small/medium-sized cutaneous T-cell lymphoma) Polycythemia vera (erythremia) Primary ... Marginal zone B-cell lymphoma Mucosa-associated lymphoid tissue lymphoma Mycosis fungoides Non-mycosis fungoides CD30− ... cutaneous lesions List of histologic stains that aid in diagnosis of cutaneous conditions List of human leukocyte antigen ...
Monomethyl auristatin E (MMAE; Vedotin) is an antimitotic agent which inhibits cell division by blocking the polymerisation of tubulin. Buy Microtubule inhibitor Monomethyl auristatin E (MMAE, Vedotin) from AbMole BioScience.
Pan, L.-Q., Wang, H.-B., Xie, Z.-M., Li, Z.-H., Tang, X.-J., Xu, Y.-C., Zhang, C., Naranmandura, H. and Chen, S.-Q. (2013), Novel Conjugation of Tumor-Necrosis-Factor-Related Apoptosis-Inducing Ligand (TRAIL) with Monomethyl Auristatin E for Efficient Antitumor Drug Delivery. Adv. Mater., 25: 4718-4722. doi: 10.1002/adma.201301385 ...
Brentuximab vedotin is a cancer medicine that interferes with the growth and spread of cancer cells in the body. Brentuximab vedotin is used to treat Hodgkins lymphoma or anaplastic large cell lymphoma. Brentuximab vedotin is given after a stem cell transplant or other cancer medications have been tried without...
PRIMARY OBJECTIVES:. I. To determine the tolerability of brentuximab vedotin given in combination with standard chemotherapy (anaplastic large cell lymphoma [ALCL]99) and to determine the tolerability of crizotinib given in combination with chemotherapy (ALCL99).. II. To estimate the event free survival (EFS) of Arm brentuximab vedotin (BV) and Arm crizotinib (CZ) and contrast these to historical control data.. SECONDARY OBJECTIVES:. I. To determine the prognostic significance of minimal disseminated disease (MDD) at diagnosis and minimal residual disease (MRD) as measured by real-time (RT)-polymerase chain reaction (PCR) in peripheral blood.. OUTLINE: Patients are assigned or randomized into 1 of 2 treatment arms.. ARM BV:. COURSE A (COURSES 1, 3, AND 5): Patients receive brentuximab vedotin intravenously (IV) over 30 minutes on day 1, dexamethasone orally (PO) twice daily (BID) or IV on days 1-5, ifosfamide IV over 60 minutes on days 1-5, methotrexate IV over 3 hours on day 1, cytarabine IV ...
Health Canada Approves ADCETRIS® (Brentuximab Vedotin) for the Treatment of Relapsed or Refractory Hodgkin Lymphoma (HL) and Systemic Anaplastic Large Cell Lymphoma (sALCL)
Purpose: The antibody-drug conjugate (ADC) brentuximab vedotin comprises a CD30-directed antibody covalently attached to the potent antimicrotubule agent monomethyl auristatin E (MMAE) via a protease-cleavable linker. This study explored the safety, maximum tolerated dose (MTD), and activity of weekly dosing of brentuximab vedotin in patients with relapsed or refractory CD30-positive hematologic malignancies. Experimental Design: In this phase 1 dose-escalation study, brentuximab vedotin was administered intravenously on Days 1, 8, and 15, of each 28-day cycle at doses ranging from 0.4 to 1.4 mg/kg. Forty-four patients were enrolled: 38 with Hodgkin lymphoma, 5 with systemic anaplastic large cell lymphoma, and 1 with peripheral T-cell lymphoma - not otherwise specified. Doses were escalated in increments of 0.2 mg/kg until dose-limiting toxicity (DLT) was observed. Patients were monitored for anti-therapeutic antibodies and pharmacokinetic parameters. Antitumor assessments were performed every 2 ...
Technology Appraisal Guidance No. 446. Source: National Institute for Health and Care Excellence. 1. Guidance. 1.1 Brentuximab vedotin is recommended as an option for treating CD30-positive Hodgkin lymphoma in adults, only if:. they have relapsed or refractory disease after autologous stem cell transplant and. the company provides brentuximab vedotin at the price agreed with NHS England in the commercial access agreement.. 1.2 Brentuximab vedotin is recommended for use within the Cancer Drugs Fund as an option for treating CD30-positive Hodgkin lymphoma in adults, only if:. ...
An antibody-drug conjugate (ADC) directed against the tumor necrosis factor (TNF) receptor CD30 with potential antineoplastic activity. Brentuximab vedotin is generated by conjugating the chimeric anti-CD30 monoclonal antibody SGN-30 to the cytotoxic agent monomethyl auristatin E (MMAE) via a valine-citrulline peptide linker. Upon administration and internalization by CD30-positive tumor cells, brentuximab vedotin undergoes enzymatic cleavage, releasing MMAE into the cytosol; MMAE binds to tubulin and inhibits tubulin polymerization, which may result in G2/M phase arrest and tumor cell apoptosis. Transiently activated during lymphocyte activation, CD30 (tumor necrosis factor receptor superfamily, member 8;TNFRSF8) may be constitutively expressed in hematologic malignancies including Hodgkin lymphoma and some T-cell non-Hodgkin lymphomas. The linkage system in brentuximab vedotin is highly stable in plasma, resulting in cytotoxic specificity for CD30-positive cells. [from NCI] ...
ANHL12P1: A Randomized Phase II Trial of Brentuximab Vedotin or Crizotinib in Combination with Chemotherapy for Newly Diagnosed Patients with Anaplastic Large Cell Lymphoma (ALCL).
We report the case of a 61-year-old woman who developed an anaplastic CD30+ cutaneous T-cell lymphoma during oral cyclosporine (CsA) therapy for recalcitrant psoriasis. Two months after CsA discontinuation, clinical and histological resolution of the
Evidence-based recommendations on brentuximab vedotin (Adcetris) for treating relapsed or refractory CD30‑positive Hodgkin lymphoma in adults
Carbonic anhydrase 9 (CAIX, carbonic anhydrase 9) is a cell surface glycoprotein that is expressed in many different tumors and yet restricted in normal tissues to the gastrointestinal tract. It is upregulated by hypoxia, and correlates with tumor grade and poor survival in several tumor indications. Monoclonal antibodies with single digit nanomolar binding affinity for CAIX were derived by panning with the recombinant ecto-domain of CAIX against the MorphoSys HUCAL Gold library of human Fabs. Highest affinity Fabs were converted to full length IgGs and subjected to further characterization based upon their avidity and selectivity for CAIX, their capacity to undergo internalization in CAIX expressing cell lines and their selective localization to CAIX positive human xenografted tumors when administered to mice as fluorescent-conjugates. Through this selection process, the 3ee9 monoclonal antibody was identified which upon conjugation to Monomethyl Auristatin E (MMAE) through a self-imolative ...
In response to cellular stress, phosphatidylserine (PS) is exposed on the outer membrane leaflet of tumor blood vessels and cancer cells, motivating the development of PS-specific therapies. The generation of drug-conjugated PS-targeting agents represents an unexplored therapeutic approach, for which anti-tumor effects are critically dependent on efficient internalization and lysosomal delivery of the cytotoxic drug. In the current study, we have generated PS-targeting agents by fusing PS-binding domains to a human IgG1-derived Fc fragment. The tumor localization and pharmacokinetics of several PS-specific Fc fusions have been analyzed in mice and demonstrate that Fc-Syt1, a fusion containing the synaptotagmin 1 C2A domain, effectively targets tumor tissue. Conjugation of Fc-Syt1 to the cytotoxic drug, monomethyl auristatin E, results in a protein-drug conjugate (PDC) that is internalized into target cells and, due to the Ca²⁺-dependence of PS binding, dissociates from PS in early endosomes. ...
Looking for medication to treat systemic+anaplastic+large+cell+lymphoma? Find a list of current medications, their possible side effects, dosage, and efficacy when used to treat or reduce the symptoms of systemic+anaplastic+large+cell+lymphoma
Ki-1 anaplastic large cell lymphoma (ALCL) commonly affects the skin, lymph nodes, and bone. Primary ALCL of the alimentary tract is rare. The authors describe a case of primary ALCL of the duodenum...
PRIMARY OBJECTIVES:. I. To estimate the maximum tolerated dose (MTD) and/or recommended Phase 2 dose of brentuximab vedotin in combination with gemcitabine administered every three weeks to children with relapsed or primary refractory Hodgkin lymphoma (HL).. II. To define and describe the toxicities of brentuximab vedotin in combination with gemcitabine administered on this schedule.. III. To determine the complete response (CR) rate after treatment with four cycles of gemcitabine with brentuximab vedotin among patients with relapsed or refractory HL.. SECONDARY OBJECTIVES:. I. To preliminarily define the antitumor activity of brentuximab vedotin in combination with gemcitabine within the confines of a Phase 1 study.. II. To describe the overall response rate (ORR) after 4 cycles of therapy among patients with relapsed or refractory HL.. III. To describe the proportion of patients with HL able to mobilize an adequate yield of cluster of differentiation (CD) 34+ stem cells after gemcitabine with ...
Previously, several groups have investigated the expression of MUC1 in malignant lymphomas. However, data on MUC1 expression in lymphomas are skewed in favour of the E29 (anti-EMA) monoclonal antibody,37 the one used most frequently in haematopathology. Furthermore, E29 does not distinguish between hyperglycosylated and hypoglycosylated MUC129; therefore, little is known about the MUC1 glycoforms present on lymphoma tumour cells. In our present study, we have used a panel of five monoclonal antibodies to study the expression and extent of glycosylation of MUC1 in ALCL and classic HD. As already described, these five antibodies all react to the immunodominant PDTRP(AP) sequence within the MUC1 protein core, but have different binding affinities, depending on the mode of glycosylation of MUC1.26,29,30,46. Our results show that MUC1, as detected by E29, DF3, and 139H2, is preferentially expressed in a subtype of systemic nodal ALCL, characterised by the presence of the ALK protein. E29 and DF3 ...
Brentuximab vedotin is a type of targeted therapy used in the treatment of Hodgkin lymphoma and systemic anaplastic large cell lymphoma.
The goal of this clinical research study is learn more about the safety of SGN-35 (brentuximab vedotin) in patients who participated in 2009-0851, were on placebo, and whose HL has gotten worse. Another goal of this study is to allow other patients with HL and ALCL whose disease has come back or is not getting better on another treatment, access to brentuximab vedotin.
OUTLINE: This is a phase I, dose-escalation study of brentuximab vedotin followed by a phase II study. (Phase I completed as of amendment 4). Patients receive brentuximab vedotin intravenously (IV) over 30 minutes on day 1 and gemcitabine hydrochloride IV over 100 minutes on days 1 and 8. Treatment repeats every 21 days for up to 16 courses in the absence of disease progression or unacceptable toxicity. Patients with CR after any course may go off protocol therapy for stem cell transplant.. After completion of study treatment, patients are followed up at 3, 6, 9, 12, 18, 24, 36, 48, and 60 months.. ...
The (2;5)(p23;q35) translocation which results in the fusion of the NPM (nucleophosmin) gene on chromosome 5q35 with the novel ALK (anaplastic lymphoma kinase) gene on chromosome 2p23 [S.W. Morris et al., Science (Washington DC), 263: 1281-1284, 1994] is associated with Ki-1 (CD30)-positive anaplastic large cell lymphomas (ALCL); a group of morphologically and immunophenotypically heterogeneous high grade large cell lymphomas (LCL), which share many characteristics with Hodgkins disease (HD), including the presence of variable numbers of Reed-Sternberg-like cells and the expression of CD30 antigen.. Using a DNA probe immediately 5′ to the NPM coding sequences, we have examined NPM gene rearrangements by Southern blotting in 5 Ki-1-positive lymphoma cell lines carrying a translocation involving the 5q35 breakpoint and in 25 Ki-positive lymphoma tumors, including 9 HD. Using this method, we detected rearrangements in all cell lines with apparent clustering of the breakpoints. Analysis of 25 ...
Press Release issued Dec 26, 2014: Global Markets Directs, Anaplastic Large Cell Lymphoma (ALCL) - Pipeline Review, H2 2014, provides an overview of the Anaplastic Large Cell Lymphoma (ALCL)s therapeutic pipeline.
A 15-year-old boy presented to us with a 4-month history of fever with worsening dyspnea since 1 month. His contrast-enhanced computed tomography scan of the thorax showed bilateral endobronchial lesions with complete collapse-consolidation of the left lung and partial collapse of the right lower lobe. His fiberoptic bronchoscopy guided biopsy had been reported in outside hospital as a neuroendocrine tumor. Due to worsening breathlessness, he had to be intubated. We repeated the endobronchial biopsy and combined with outside slides and blocks, was diagnosed to have an anaplastic lymphoma kinase-1 positive anaplastic large cell lymphoma (ALCL ...
Potentials of brentuximab vedotin in the treatment of relapse/refractory cutaneous T-cell lymphomas: literature review and authors observation
Anaplastic large cell lymphoma (ALCL) is an aggressive CD30+ T-cell lymphoma that accounts for 2-8% and 10-15% of non-Hodgkin lymphomas in adults and children, respectively. The currently used standard therapy for anaplastic lymphoma kinase (ALK, a member of the insulin receptor superfamily) positive ALCL has limited effectiveness, resulting in a substantial percentage of cases with poor outcomes, either failing to enter remission or relapse within a few months after starting treatment. Thus, there is a clear unmet clinical need for developing novel, effective and safer therapeutic strategies for ALCL. Nucleophosmin 1 (NPM1) is a nucleolar phosphoprotein, which functions as a molecular chaperone for proteins and nucleic acids. Approximately 50% of ALCL cases are positive for the NPM1-ALK fusion chimera generated by the t(2;5) chromosomal translocation. The oligomerization domain of NPM1 in the fusion protein NPM1-ALK mediates the ligand-independent dimerization of chimeric protein, which results ...
polyneuropathy, ALT/AST increased, rash, and back pain. ADCETRIS (brentuximab vedotin) U.S. Important Safety Information BOXED WARNING: PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML) ...
All information about the latest scientific publications of the Clínica Universidad de Navarra. Transcripts of the npm-alk fusion gene in anaplastic large cell lymphoma, Hodgkins disease, and reactive lymphoid lesions
Food and Drug Administration has expanded the indication for brentuximab vedotin - in combination with chemotherapy - to certain types of peripheral T-cell lymp
Seattle Genetics Reports Data from Phase I Trial of ADCETRIS ® (Brentuximab Vedotin) in Front-line Mature T-Cell Lymphomas (MTCL) -100 Percent Objective Response Rate, Including 88 Percent
The drug being tested in this study is called brentuximab vedotin. Brentuximab vedotin is being tested to treat pediatric participants who have advanced stage, newly diagnosed, classical CD30+ HL. This study will assess the safety, tolerability, and anti-tumor activity, as well as recommended dose of brentuximab vedotin in combination with a multiagent chemotherapy regimen that is based on a current standard of care (SOC) first-line treatment regimen for newly diagnosed HL. The study will enroll approximately 55 evaluable participants. The study will be conducted in 2 phases, Phase 1 and Phase 2. Phase 1 study will enroll up to 12 participants to determine the recommended dose. Once the recommended dose is identified additional participants will be enrolled into phase 2 so that the total number of evaluable participants will be approximately 55, including participants treated at recommended dose in Phase 1. Participants will be enrolled in the following 2 dose Cohorts: • Brentuximab vedotin 48 ...
Certain of the statements made in this press release are forward looking, such as those, among others, relating to the therapeutic potential of ADCETRIS (brentuximab vedotin) including relating to the overall survival rates in HL following treatment with ADCETRIS, future clinical trials and possible uses in disease settings other than those already approved. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include that the historical results in clinical trials for ADCETRIS may not predict results in ongoing or future clinical trials of ADCETRIS and the data resulting from additional trials with ADCETRIS may not support approvals in the studied indications and the possibility of newly detected adverse safety events and adverse regulatory action. More information about the risks and uncertainties faced by Seattle Genetics is contained under the caption "Risk Factors" included in the ...
T cell-derived malignant lymphoma is rarely detected as a bladder neoplasm. A literature review for anaplastic large cell lymphoma (ALCL) involving urinary bladder reveals only seven previously reported cases. Here, we report a case of a 59-year-old
Anaplastic large cell lymphoma (ALCL) is quite rare. It is more likely to affect children and young adults, and is more commonly found in males.
Anaplastic large cell lymphoma arises in thymocytes and requires transient T cell receptor expression for thymic egress. . Biblioteca virtual para leer y descargar libros, documentos, trabajos y tesis universitarias en PDF. Material universiario, documentación y tareas realizadas por universitarios en nuestra biblioteca. Para descargar gratis y para leer online.
ICD-9 200.62 is anaplastic large cell lymphoma, intrathoracic lymph nodes (20062). This code is grouped under diagnosis codes for neoplasms.
SummaryAnaplastic lymphoma kinase (ALK), which belongs to the insulin receptor tyrosine kinase superfamily, plays an important role in nervous system development. Due to chromosomal translocations, point mutations, and gene amplification, constitutively activated ALK has been implicated in a variety of human cancers, including anaplastic large-cell lymphoma (ALCL), non-small cell lung cancer, and ...
Downregulation of MicroRNA-455-3p Links to Proliferation and Drug Resistance of Pancreatic Cancer Cells via Targeting TAZ Investigators demonstrated that transcriptional co-activator with PDZ-binding motif (TAZ), which is associated with drug resistance of pancreatic cancer, is a new direct downstream target of miR-455-3p. [Mol Ther Nucleic Acids] Full Article Targeted Delivery of Auristatin-Modified Toxins to Pancreatic Cancer Using Aptamers Scientists assayed the toxicity of monomethyl auristatin E and monomethyl auristatin F conjugated to an anti-transferrin receptor aptamer, Waz, and an anti-epidermal growth factor receptor aptamer, E07, on the pancreatic cancer cell lines Panc-1, MIA PaCa-2, and BxPC3. [Mol Ther Nucleic Acids] Full Article Carnitine Palmitoyltransferase 1C Regulates Cancer Cell Senescence through Mitochondria-Associated Metabolic Reprograming The authors showed that carnitine palmitoyltransferase 1C, an enzyme that catalyzes carnitinylation of fatty acids for transport into ...
If you havent heard of Dr. Clay Siegall, he is the Founder and CEO of Seattle Genetics, a biotechnology company predicated on the development of targeted therapy drugs. In laymans terms, these are drugs aimed at delivering a concentration of medication to a specific part of the body, localized cancers being a primary example. Since being founded in 1998, Dr. Siegall and his team at Seattle Genetics have worked diligently towards creating pharmacotherapies aimed at improving mortality rates, in those who have been diagnosed with serious diseases. In fact, in November 2017, Seattle Genetics received FDA approval for one of their antibody drug conjugates, Adcetris. The drug is reportedly used to treat patients diagnosed with Hodgkin lymphoma and systemic anaplastic large cell lymphoma.. According to his Linkedin bio, Dr. Siegall attended George Washinton University, where he earned a Ph.D. in Genetics. Shortly thereafter, he earned a B.S. in Zoology from the University of Maryland. In an ...
The FDA has accepted Seattle Genetics sBLA for filing of Adcetris for retreatment and extended duration beyond 16 cycles of therapy in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma.
Results: Median time to relapse after ASCT was 6.7 mos (range, 0-131). Pts received a median 9 cycles of Brentuximab Vedotin. The ORR was 75% (76/102 pts), with complete remissions (CRs) in 34 pts (33%). At time of analysis (July 2012), the median time from first dose was 29.5 mos (range, 1.8-36.9). 60/102 pts (59%) were alive at the time of last follow up and median overall survival (OS) has not been reached. The estimated 24-mo OS was 65% (95% CI: 55, 74). The median OS by best clinical response was 31.6 mos for pts with partial remission (PR, n=42), 20.6 mos for pts with stable disease (SD, n=22), and 10.2 mos for pts with progressive disease (PD, n=3); median OS for pts with CR (n=34) has not been reached. Evaluation of demographic and baseline characteristics found that pts with a baseline ECOG score of 0 were the only subgroup with a significantly more favorable OS following Brentuximab Vedotin treatment (24-mo OS: 81% vs. 47% for ECOG scores of 0 vs 1, respectively). There was no ...
In this piece, I address my own experience with cancer by revisiting the original CT Scan of my tumor. This scan was taken prior to my diagnosis, and shows the tumor at its largest. Through the appropriation of this scan, I am taking control of my cancer and recontextualizing the experience of the tumor removal. In the piece, I utilize laser cutting in order to remove the tumor from my pelvis. The laser cutter has the ability to remove the mass with more precision than the human hand, and can also replicate the same cut over and over again. Because of the way the growth had wrapped itself around major arteries, the surgeons had to be delicate and precise when removing the mass. The laser also cauterizes the edges of the fabric, preventing the area where the tumor outline used to be, from fraying. This effect helps the fabric maintain the original form of the tumor.. Laser Cut Cyanotypes on ...
Wolters Kluwer Health may email you for journal alerts and information, but is committed to maintaining your privacy and will not share your personal information without your express consent. For more information, please refer to our Privacy Policy ...
Although brentiximab vedotin is approved in Europe by the European Medicines Agency and included in the United Kingdoms Old Cancer Drugs Fund (CDF), a fund designed pay for cancer drugs that are not available on the National Health Service (NHS), the new NICE draft guidance to not recommend the drug, has angered both physicians and patients organizations in the United Kingdom as well as Takeda Pharmaceutical Co, the drugs co-developer and distributor outside North America.*** They argue that, if made final in February 2017, a negative decision in England could ultimately mean that patients with relapsed or refractory Hodgkin lymphoma may be denied access to a drug that has changed the treatment option and survival outlook for many patients.. In addition, a negative decision by NICE, they contend, could lead to inequality of care in the United Kingdom as access to the initial indications for brentuximab vedotin has been approved in Scotland and Wales.. But the concern, which is not limited to ...
The primary objective of this study is to determine the maximum tolerated dose (MTD) and safety and tolerability of MEDI-507 in patients with CD2-positi
Lymphoma, Gene, Lymphomas, Cell, Cells, Virus, Classification, In Situ Hybridization, Anaplastic Large Cell Lymphoma, Binding Protein, Large Cell Lymphoma, Transcription Factor, Antibodies, Calcium, Regulation, Cyclin, Cyclin D1, Germinal Center, Incidence, Phenotype
Takeda Receives European Commission Approval of ADCETRIS® (brentuximab vedotin) for Consolidation Treatment in Post-Transplant Hodgkin Lymphoma
Purpose : Bacterial Transglutaminase (BTG) allows coupling on endogenous Q295 from an aglycosylated antibody. Here, the work relates to ADCs synthesis through BTG approach on mAbs with single point mutations and the study of stability, pharmacokinetics, as well as in vitro and in vivo efficacy of resulting BTG-ADCs. AdcetriS®, brentuximab vedotin, has been used as comparator, hence for consistency BTG-ADCs have been conjugated with the different linkage strategies (one step and two step) containing distally the same protease sensitive moiety compared to ADCETRIS®, i.e. valine-citrulline-PAB-MMAE.. Methods : . For synthesis, a two-step process has been designed consisting of coupling first a linker and coming back with a toxin, and affording versatility and efficiency. The DAR stability was monitored over one week in human and cynomolgus plasma by affinity capture/LC/MS. The pharmacokinetic profile was studied in rat and monitored by affinity capture/LC/MS for conjugated antibody and ELISA for ...
Discovery of recurrent t(6;7)(p25.3;q32.3) translocations in ALK-negative anaplastic large cell lymphomas by massively parallel genomic sequencing. Feldman AL, Dogan A, Smith DI, Law ME, Ansell SM, Johnson SH, Porcher JC, Ozsan N, Wieben ED, Eckloff BW, Vasmatzis G. Blood. 2011 Jan 20;117(3):915-9. doi: 10.1182/blood-2010-08-303305. PMID: #21030553# (...). ...
Dr. Dansie responded: Very specific. This is a very specific question and cant be answered adequately in 400 characters. You should really ask this question to your treating physician since they will know all the specifics of your particular case.
A new publication from Celon Pharma S.A. laboratories! (3/31/2014) - Our new publication on experimental oncology has just appeared! The article entitled "Activating mutations in ALK kinase domain confer resistance to structurally unrelated ALK inhibitors in NPM-ALK-positive anaplastic large-cell lymphoma." by Daria Zdzalik and co-workers was published in Journal of Cancer Research and Clinical Oncology and is freely available via … ...
Introduction. Cutaneous CD30 positive lymphoproliferative disorders encompass a broad range of diseases, including primary cutaneous anaplastic large-cell lymphoma (pcALCL), lymphomatoidpapulosis, tumor transformation of mycosis fungoides or borderline disorders. These diseases have multiple clinical and histopathological variants, partly overlapping, but different prognosis and management. They must also be differentiated from the secondary skin determinations of systemic lymphomas. Thus their precise diagnosis and correct classification is essential for the patients best care, but is challenging for the practitioner and needs careful and close correlation between clinical and pathological evaluation. ...
TY - JOUR. T1 - Breast implant-associated anaplastic large cell lymphoma. T2 - A systematic review. AU - Leberfinger, Ashley N.. AU - Behar, Brittany J.. AU - Williams, Nicole C.. AU - Rakszawski, Kevin L.. AU - Potochny, John D.. AU - MacKay, Donald R.. AU - Ravnic, Dino J.. PY - 2017/12. Y1 - 2017/12. N2 - IMPORTANCE Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), a rare peripheral T-cell lymphoma, is increasing in incidence. However,many practitioners who treat patients with breast cancer are not aware of this disease. OBJECTIVES To assess how BIA-ALCL develops, its risk factors, diagnosis, and subsequent treatment and to disseminate information about this entity to the medical field. EVIDENCE REVIEW A literature review was performed in an academic medical setting. All review articles, case reports, original research articles, and any other articles relevant to BIA-ALCL were included. Data on BIA-ALCL, such as pathophysiology, patient demographics, presentation, ...
The cytokine soluble CD23 (sCD23) has been shown to act as a B cell growth factor and to be elevated in serum prior to development of AIDS-related non-Hodgkins lymphoma (AIDS NHL). To further characterize the elevation of serum sCD23 in AIDS NHL patients and investigate its potential as a diagnostic test, a matched case-control study of AIDS NHL (n = 101) was nested within the Multicenter AIDS Cohort Study. Serum sCD23 was measured in cases and controls serum specimens at three different time periods (0-6, 6-12, and 12-18 months) and CD4+ thresholds (0-99, 100-199, and 200-299 cells/microl) prior to the cases NHL diagnosis. Changes in serum sCD23 over time were examined in AIDS NHL cases relative to controls, and t tests were performed to determine whether cases serum sCD23 exceeded that of controls at each time period and CD4+ threshold. Overall, cases median serum sCD23 levels were approximately double those of controls. Serum sCD23 concentration was positively correlated with lymphocyte counts
BACKGROUND AND OBJECTIVES: Anaplastic lymphoma kinase (ALK) oncogenic fusion proteins, expressed in about 60% of anaplastic large cell lymphomas (ALCL), are tumor-specific molecular targets for such a malignancy. One of the promising ALK-targeted therapeutic options is cancer vaccination. In this study, we investigate whether ALK is a tumor-associated antigen suitable for immune interventions. DESIGN AND METHODS: The frequency and the functional phenotype of the anti-ALK CD8 precursor repertoire in freshly isolated peripheral blood mononuclear cells (PBMC) from healthy donors and ALK-positive patients were determined by major histocompatibility complex (MHC)/tetrameric analyses. The anti-ALK secondary immune responses were evaluated as PBMC-specific interferon (INF-gamma) release by ELISPOT. In addition, the ability of the anti-ALK immune response to specifically lyse ALK-positive lymphoma cells was investigated by in vitro stimulation with ALK-derived peptide p280-89. RESULTS: Tetrameric ...
The goal of this clinical research study is to learn if SGN-35 (brentuximab vedotin) can help to control ALCL, LyP or MF in patients with at least 1 of
Lawsuit information regarding anaplastic large cell lymphoma from Roundup weed killer. Contact a lawyer to see if you have a Roundup Cancer Lawsuit.
In this interview we discuss the link between breast implants and anaplastic large-cell lymphoma, a rare type of T-cell lymphoma. 1
Brentuximab vedotun was recently approved by the FDA for transplant-ineligible and transplant-failing Hodgkin lymphoma (HL) patients. Three abstracts at the ASH meeting regarding this agent are noteworthy.. Younes et al (Abstract 955) combined brentuximab vedotin with ABVD or AVD in patients with advanced stage, untreated HL. Interim data on the first 31 patients were presented, and there are mixed messages. This was a planned ABVD study, but seven of the first 19 patients had significant pulmonary toxicity that included interstitial lung disease leading to a protocol amendment eliminating bleomycin.. Thus far all evaluable patients are in complete remission, which is encouraging. However, there needs to be extreme caution when combining brentuximab vedotin with any agent that has the propensity to cause pulmonary toxicity, including gemcitabine. The role of brentuximab vedotin as part of combined modality (chemotherapy and radiation) approaches for HL clearly needs to be studied. There were two ...
Lymphomatoid papulosis (LyP) is a recurrent hemorrhagic papular skin eruption with a clinically benign course and histopathologic features of lymphoma. Dermatopathology patterns that remind us of something else. The lesions usually present as papules and nodules that spontaneously involute. Initially the lesions are smooth but later these lesions become crusted, ulcerated and necrotic.. Lymphomatoid papulosis can only be diagnosed accurately through a careful history in which the characteristic waxing and waning of the skin lesions is identified and through proper communication between clinicians and pathologists.. Age: Usually occurs in the third and fourth decade of life. This lesion may also occur in children.. Site: Trunk ; Proximal parts of the limb ; face ; scalp ; palms and sole.. Microscopic features: Subtypes- LyP Type A ; LyP Type B ; LyP Type C ; LyP Type D LyP Type A : Wedge-shaped, superficial and deep mixed infiltrate of small lymphocytes, abnormal lymphocytes and, often, plasma ...
Hepatitis B virus (HBV) infection is a major cause of chronic liver diseases including hepatocellular carcinoma (HCC). CD14 and its soluble form sCD14 play important roles in immunity and are...
Adverse Reactions In two uncontrolled single-arm trials of ADCETRIS as monotherapy in 160 patients with relapsed classical HL and sALCL, the most common adverse reactions (≥20%), regardless of causality, were: neutropenia, peripheral sensory neuropathy, fatigue, nausea, anemia, upper respiratory tract infection, diarrhea, pyrexia, rash, thrombocytopenia, cough and vomiting. In a placebo-controlled trial of ADCETRIS in 329 patients with classical HL at high risk of relapse or progression post-auto-HSCT, the most common adverse reactions (≥20%) in the ADCETRIS-treatment arm (167 patients), regardless of causality, were: neutropenia, peripheral sensory neuropathy, thrombocytopenia, anemia, upper respiratory tract infection, fatigue, peripheral motor neuropathy, nausea, cough, and diarrhea. Drug Interactions Concomitant use of strong CYP3A4 inhibitors or inducers, or P-gp inhibitors, has the potential to affect the exposure to monomethyl auristatin E (MMAE). Use in Specific Populations MMAE ...
According to survival results from a phase II trial of brentuximab vedotin (Adcetris; Seattle Genetics/Takeda), a sizeable fraction of patients with classic Hodgkin lymphoma (cHL) who had a complete response to this CD30-targeting antibody-drug conjugate are still in remission 5 years later.. "Practically speaking, if one stays in complete response for more than 5 years, the term cure can be used," says senior author Anas Younes, MD, chief of the lymphoma service at Memorial Sloan Kettering Cancer Center in New York, NY.. In 2011, based on data from this study, brentuximab vedotin received accelerated FDA approval to treat patients with relapsed or refractory cHL whose disease had progressed following an autologous stem cell transplant (auto-SCT, using ones own hematopoietic stem cells) or-if unsuitable for auto-SCT-at least two multichemotherapy regimens. The agencys nod stemmed from an objective response rate of 75% among 102 patients, including 34 complete responses.. Younes and ...
The key clinical feature of the case is an enlarging solitary skin nodule on his left cheek, with no other discomfort or systemic involvement. The differential diagnosis includes skin malignancy, juvenile xanthogranuloma, mastocytosis, angioma, dermatofibroma and Langerhans cell histiocytosis. Surgical resection of the entire nodule was performed for pathological diagnosis and management strategy.. Microscopically, H&E staining revealed a dense non-epitheliotropic infiltrate of small-to-medium-sized atypical T-cells. The infiltrate showed a nodular pattern in the dermis and subcutis. Immunohistochemistry showed neoplastic cells were CD3+/CD4+/CD2+/CD5+ and CD8 (−)/CD30 (−)/CD56 (−)/TIA-1 (−)/CD20 (−)/CD7 (−). The proliferative marker, Ki-67, showed a low nuclear reaction involving 10% neoplastic cells (figure 2). In situ hybridisation for Epstein-Barr virus (EBV) was negative. Clonal TCR gene rearrangements were detected (figure 3). The diagnosis of primary cutaneous … ...
VAŽNOST CITOLOŠKE ASPIRACIJSKE PUNKCIJE TANKOM IGLOM U DIJAGNOSTICI HOGKINOVOG LIMFOMA I ANAPLASTIČNOG VELIKOSTANIČNOG LIMFOMA: ISKUSTVO JEDNOG KLINIČKOG CENTRA ----- Cilj studije bio je procijeniti vrijednost i ograničenja citologije u dijagnostici i razlikovanju Hodgkinovog limfoma (HL) i anaplastičnog velikostaničnog limfoma (ALCL). Analizirali smo početne citološke dijagnoze, rezultate patohistološke obrade, učinke terapije i preživljenje u 89 novodijagnosticiranih bolesnika s tim limfomima koji su liječeni na našem kliničkom odjelu. U 89 bolesnika (40 muškaraca, 49 žena; u dobi od 16 do 93 godine; 44 u kliničkom stadiju I-II, 38 s B simptomima) bila je postavljena dijagnoza i liječeni su u vremenskom razdoblju od 64 mjeseca (1.1.2004.-1.5. 2009. god.). Citološka dijagnostika bila je moguća u 86 bolesnika, a patohistološku dijagnozu bilo je moguće postaviti kod 84 bolesnika. Citološka aspiracijska punkcija otkrila je 65 klasičnih HL-a, 18 ALCL-a, a u 3 bolesnika ...
Diagnosis Code C84.62 information, including descriptions, synonyms, code edits, diagnostic related groups, ICD-9 conversion and references to the diseases index.
Introduction: The phosphatidylinositol 3-kinase (PI3K) pathway is consistently activated in relapsed/refractory Hodgkin lymphoma (HL). Expression of the δ and γ isoforms of PI3K is restricted to cells of the hematopoietic system, suggesting that RP6530, a novel dual PI3K δ/γ Inhibitor, might represent a promising approach in the treatment of lymphomas. The CD30-directed antibody-drug conjugate, Brentuximab Vedotin (BV), has recently been reported to induce a high overall response rate in relapsed/refractory HL, but is associated with limited response duration. Combination therapies aimed at enhancing the anti-tumor activity of BV and eventually reducing its side effects may have significant clinical impact in the treatment of relapsed/refractory HL. Our study aimed at investigating the activity and mechanism(s) of action of RP6530 in combination with BV in preclinical HL models.. Methods and Results: RP6530 was active against a panel of HL cell lines (L-540, KM-H2, L-428). Using a WST assay, ...
The course of mycosis fungoides (MF) is indolent except when transformation to a large T-cell lymphoma occurs. The diagnosis of transformed MF relies on the presence of more than 25% of large cells on biopsy of an MF lesion View […]
Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that more than a dozen abstracts, in addition to several collaborator abstracts, for both ADCETRIS (brentuximab vedotin) and investigational antibody-drug ......SGEN
BRENTUXIMAB VEDOTIN, 1 INDICATIONS AND USAGE ADCETRIS is a CD30-directed antibody-drug conjugate indicated for treatment of patients with: Classical Hodgkin lymphoma (HL) after failure of autologous hematopoietic stem cel
This randomized phase III trial compares immunotherapy drugs (nivolumab or brentuximab vedotin) when given with combination chemotherapy in treating patients with newly diagnosed stage III or IV classic Hodgkin lymphoma.
The EC granted conditional approval for Seattle Genetics and Millenniums antibody-drug conjugate (ADC) Adcetris (brentuximab vedotin) for two lymphoma indications.
3. Nivolumab (anti PD-1 monoclonal antibody) in post-transplant relapse: Hodgkins lymphoma is an ideal model for immune checkpoint modulation due to high immunocyte infiltration around the tumor cells. There is a Phase 1 study with up to 80% response rate in heavily pretreated patients (including patients previously treated with Brentuximab Vedotin). This is the most exciting result in lymphoma in this ASH 2014 (NEJM On-line first). ...
Tumors, Anaplastic Large-cell Lymphoma, Antigen, Cd30 Antigen, Hodgkins Lymphoma, Lymphoma, Chemotherapy, History, Hodgkin Lymphoma, Natural History, Apoptosis, Cell, Ubiquitin, Identification, and Cell Death
I have to admit that when I first read about the FDAs report tying rare cases of anaplastic large cell lymphoma to breast implants, my mind raced with a strange blend of excitement, intense interest and concern. My thoughts shifted from "wow, thats really interesting" to "exactly what did the FDA find" to "should I be worried?". So Ive decided to write this mornings post from my perspective as an oncologist who spent roughly 15 years of her life studying the causes of lymphomas and related blood malignancies. Some readers of this blog, who fortunately at this point in MLs slow-but-steady growth are mainly strangers, may be unaware that understanding rare lymphomas was what I lived for in my research work, which occupied the bulk of my time and thought, which I loved very much (as strange as that may seem to some) and which I miss intensely, still, today.. The reality, as very-carefully documented by the FDA in its excellent analysis (which, in my opinion, far surpasses that of most case ...
Including the modified brentuximab antibody in the treatment regimen improved modified progression-free survival in patients witb Advanced Hodgkin Lymphoma.
പദാർത്ഥത്തിന്റെ അവസ്ഥയെയും (ഖരം, ദ്രാവകം, വാതകം) താപനിലയെയും ആശ്രയിച്ച് മൂന്ന് ഘടനകൾ സ്വീകരിക്കാൻ AlCl3ന് സാധിക്കും. ഖരാവസ്ഥയിലുള്ള AlCl3, ഷീറ്റിന് സമാനമായ പാളികളുള്ള ഘനരൂപമായി കാണപ്പെടുന്നു. ഈ അവസ്ഥയിൽ അലൂമിനിയം, അഷ്ടമുഖ ഏകോപന ജ്യാമിതിയായി കാണപ്പെടുന്നു.[7] ദ്രവീകരിച്ച അവസ്ഥയിൽ അലൂമിനിയം ട്രൈക്ലോറൈഡ് ഒരു ഡിമർ Al2Cl6 ആയി ടെട്രാകോർഡിനേറ്റ് അലൂമിനിയം കാണപ്പെടുന്നു. ...
Primary cutaneous anaplastic large cell lymphoma (PC-ALCL) is a rare type of non-Hodgkins lymphoma comprising approximately 0.9 - 9.0% of all cutaneous lymphomas. 75% of them are CD30 positive. PCALCL is characterized by the absence of systemic involvement, spontaneous regression and low recurrence rate especially in localized lesions. We present a 33-year-old male with a 1-year history of asymptomatic, well-defined, systemic involvement, diameter of 2 - 6 cm, irregularly-shaped erythematous plaques. Skin punch biopsy revealed dense infiltrates of non-epidermotropic, large, irregularly-shaped lymphocytes with hyperchromatic and pyknotic nuclei. Immunohistochemistry revealed that these atypical cells are CD3(+), CD5 dispersion (+), CD20(- ), CD79a(-), Ki-67(-), TdT(-), CD10(-), Bcl-6(-), CyclinD1(-), CD138 dispersion (+), MUM1(-), mitochondrial enzymes B(+), TIA-1(+++), CD4(++), CD8 dispersion(+), CD30(-), CD56(-). Clinical, histopathological and immunohistochemical findings are consistent with PC
Cytologically, the neoplastic cells are large, highly atypical cells with very irregular, pleomorphic nuclei with dispersed chromatin and one to several nucleoli and abundant pale to eosinophilc cytoplasm ...
In patients with Hodgkin lymphoma who are at risk for disease progression following autologous stem cell transplantation, early consolidation with brentuximab vedotin (Adcetris) post-transplant significantly improved progression-free survival compared with placebo in the phase III AETHERA trial.1 The median progression-free survival was 43 months for the brentuximab-treated group vs 24 months for the placebo group, representing a significant 43% reduction in the risk of disease progression (P = .001).. "In my opinion, once this study is published, brentuximab should be the standard of care for patients with the characteristics in this trial: that is, remission duration less than 1 year, extranodal disease, B symptoms, two or more prior salvage therapies, and primary refractory disease," said lead author Craig Moskowitz, MD, Clinical Director of the Division of Hematologic Oncology at Memorial Sloan Kettering Cancer Center, New York.. Dr. Moskowitz explained that autologous stem cell ...
Anaplastic large cell lymphomas (ALCLs) are CD30-positive T-cell non-Hodgkin lymphomas broadly segregated into ALK-positive and ALK-negative types. Although ALK-positive ALCLs consistently bear rearrangements of the ALK tyrosine kinase gene, ALK-negative ALCLs are clinically and genetically heterogeneous. About 30% of ALK-negative ALCLs have rearrangements of DUSP22 and have excellent long-term outcomes with standard therapy. To better understand this group of tumors, we evaluated their molecular signature using gene expression profiling. DUSP22-rearranged ALCLs belonged to a distinct subset of ALCLs that lacked expression of genes associated with JAK-STAT3 signaling, a pathway contributing to growth in the majority of ALCLs. Reverse-phase protein array and immunohistochemical studies confirmed the lack of activated STAT3 in DUSP22-rearranged ALCLs. DUSP22-rearranged ALCLs also overexpressed immunogenic cancer-testis antigen (CTA) genes and showed marked DNA hypomethylation by reduced ...
Primary non-Hodgkin lymphoma (NHL) of the breast represents 0.04-0.5% of malignant lesions of the breast and accounts for 1.7-2.2% of extra-nodal NHL. Most primary cases are of B-cell phenotype and only rare cases are of T-cell phenotype. Anaplastic large cell lymphoma (ALCL) is a rare T-cell lymphoma typically seen in children and young adults with the breast being one of the least common locations. There are a total of eleven cases of primary ALCL of the breast described in the literature. Eight of these cases occurred in proximity to breast implants, four in relation to silicone breast implant and three in relation to saline filled breast implant with three out of the eight implant related cases having previous history of breast cancer treated surgically. Adjuvant postoperative chemotherapy is given in only one case. Secondary hematological malignancies after breast cancer chemotherapy have been reported in literature. However in contrast to acute myeloid leukemia (AML), the association between
BIA-ALCL aka Breast Implant Associated Anaplastic Large Cell Lymphoma is an extremely rare tumor that can develop around breast implants. Heres the latest info
BOTHELL, Wash.--(BUSINESS WIRE)--Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that the U.S. Food and Drug Administration (FDA) has approved ADCETRIS (brentuximab vedotin) for the treatment of adult patients with primary cutaneous anaplastic large cell lymphoma (pcALCL) and CD30-expressing mycosis fungoides
The CD4+ PCSM-TLPD was first described in 1995 by Friedmann et al. [2] as a primary cutaneous CD4+ small/medium T-cell lymphoma, and this entity was classified as a provisional lymphoma in the previous WHO classification [3]. Patients with CD4+ PCSM-TLPD usually present with solitary, reddish tumors, commonly located on the head and neck, with rare instances of ulceration. Spontaneous resolution was observed after an incisional biopsy, and the overall 5-year survival rate was reported to be 60-100%. In particular, the localized lesions showed excellent prognosis, prompting some to consider CD4+ PCSM-TLPD to be a form of reactive lymphoid lesion. With the present knowledge, it remains unclear if CD4+ PCSM-TLPD is a precursor of lymphoma, representing a subtype of cutaneous T-cell lymphoma, or if it is an entirely benign reactive condition (pseudolymphoma) [4].. Garcia-Herrera et al. [5] reported five patients who died of CD4+ PCSM-TLPD. The patients with poor prognosis had characteristic ...
Thank you for your interest in spreading the word on JIM.. NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.. ...
PURPOSE Antibody-drug conjugates (ADC) selectively deliver a cytotoxic drug to cells expressing an accessible antigenic target. Here, we have appended monomethyl auristatin E (MMAE) to an antibody recognizing the SLC34A2 gene product NaPi2b, the type II sodium-phosphate cotransporter, which is highly expressed on tumor surfaces of the lung, ovary, and thyroid as well as on normal lung pneumocytes. This study evaluated its efficacy and safety in preclinical studies. EXPERIMENTAL DESIGN The efficacy of anti-NaPi2b ADC was evaluated in mouse ovarian and non-small cell lung cancer (NSCLC) tumor xenograft models, and its toxicity was assessed in rats and cynomolgus monkeys. RESULTS We show here that an anti-NaPi2b ADC is effective in mouse ovarian and NSCLC tumor xenograft models and well-tolerated in rats and cynomolgus monkeys at levels in excess of therapeutic doses. Despite high levels of expression in normal lung of non-human primate, the cross-reactive ADC exhibited an acceptable safety profile
CD30 / TNFRSF8 (Hodgkin & Reed-Sternberg Cell Marker) Antibody - Culture Supernatant , Mouse Monoclonal Antibody [Clone Ber-H2 ] validated in IHC, IF, FC (AH12687-01), Abgent
Answer: There were several updates of both company-sponsored (e.g. the AETHERA trial) and investigator developed prospective clinical trials that further indicate the efficacy and safety of the use of brentuximab vedotin in patients with relapsed / refractory (r/r) Hodgkin lymphoma. The results of these studies will further improve the outcome of r/r Hodgkin lymphoma patients.. Question: What are the benefits of these engineered and complex novel drugs in the treatment of Hodgkin lymphoma and other cancers?. Answer: They represent a completely different way to treat patients with Hodgkin lymphoma (and other types of hematological malignancies that express the CD30 antigen in the cell surface). It represents a very intelligent way to deliver high doses of a very potent cytotoxic agent without giving the patient significant toxicity.. CD30 is a cell surface antigen expressed on malignant HL Reed-Sternberg cells and targeted by brentuximab vedotin, which comprises a CD30-targeted monoclonal ...
In the WHO classification,2 ALCL is divided into cutaneous and systemic types, with the latter further delineated by the presence or absence of ALK protein expression. The presence of ALK protein defines a group with an excellent prognosis when treated with standard chemotherapy.8⇓-10,22 Our results confirm the distinctive clinical features of ALK+ ALCL, because our patients were younger and had a more favorable prognosis compared with ALK− ALCL or PTCL-NOS. However, this favorable prognosis may be largely dictated by the younger age at presentation, as we found no outcome differences when the analysis was limited to ALCL patients aged 40 years and older. Interestingly, patients with stage III disease had a better outcome compared with those with stage IV disease in ALK+ ALCL, a feature further highlighted by the prognostic importance of multiple extranodal sites of involvement. Prior studies have suggested that extranodal disease is more prevalent in ALK+ ALCL.8,16 However, in the present ...
LRF is the largest non-profit organization in the nation devoted exclusively to funding innovative lymphoma research and providing people with lymphoma and healthcare professionals with up-to-date information about this type of cancer. The mission of LRF is to eradicate lymphoma and serve those touched by this disease.
Learn about ADCETRIS® (brentuximab vedotin) for the treatment of adult patients with CD30-positive mycosis fungoides (MF) or primary cutaneous anaplastic large cell lymphoma (pcALCL) who have received prior systemic therapy.
Seattle Genetics Announces FDA Approval of ADCETRIS® (Brentuximab Vedotin) for Primary Cutaneous Anaplastic Large Cell Lymphoma (pcALCL) and CD30-Expressing Mycosis Fungoides (MF) (11-15-2017) -MF and pcALCL Represent the Most Common Subtypes of Cutaneous T-Cell Lymphoma (CTCL)- -FDA Approval Based on Clinical Trial Results from the Phase 3 ALCANZA and Phase 2 Investigator-Sponsored Studies in CTCL- "Cutaneous T-cell lymphoma is a blood cancer... Continue Reading. ...
Last month the U. S. Food and Drug Administration updated its 2011 safety announcement regarding breast implant associated anaplastic large-cell lymphoma (BIA-ALCL). Since this update, there have been a few news articles published that have caused some fear and concern among some of our patients. We want to provide some facts and information about this disease.. This is what is currently known about Breast implant associated anaplastic large cell-lymphoma (BIA-ALCL). It is a rare ( 1 in 500,000 to 3 million) and very treatable T-cell lymphoma that can develop around breast implants. It is not a cancer of the breast tissue. In case studies performed, the ALCL cells were found in the fibrous scar capsule surrounding the implant. Most of the women who were diagnosed had fluid that had collected around their implant (known as a seroma). Symptoms present as pain, persistent swelling of the breast, or a lump in the breast or underarm. These symptoms often occur years after the placement of the implant ...
The aim of this study was to improve the level of diagnosis and differential diagnosis of lymphomatoid papulosis (LyP). Two cases of type B LyP were identified and the literature was reviewed to summarize the clinical outcomes and pathology of LyP and its treatment. The two patients exhibited symptoms with papulonodular lesions, the centers of which gradually underwent ulceration and necrosis. CD30, a helper T-cell marker specifically expressed in tumor cells was analyzed by immunohistochemical staining and the result showed that CD30-negative or only scattered CD30-positive cells were present. Therefore, a diagnosis of type B LyP was made. A fairly good curative effect was achieved following treatment with retinoic acid, glucocorticoids and immunomodulatory drugs. LyP is a type of low-level malignant lymphoma and is easily misdiagnosed as pityriasis lichenoides et varioliformis acuta and other diseases. In order to avoid under diagnosis and misdiagnosis, doctors should evaluate suspected ...
Cutaneous T-cell lymphoma is a general term for lymphomas of the skin including mycosis fungoides, Sézary syndrome, lymphomatoid papulosis, cutaneous anaplastic large cell lymphoma, adult T-cell leukemia/lymphoma, peripheral T-cell lymphoma, lymphomatoid granulomatosis, granulomatous slack skin disease, and pagetoid reticulosis.
[65 Pages Report] Check for Discount on Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Pipeline Review, H1 2018 report by Global Markets Direct. Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or...

Primary CD30 (Ki-1)-positive anaplastic large cell lymphoma of the duodenum | SpringerLinkPrimary CD30 (Ki-1)-positive anaplastic large cell lymphoma of the duodenum | SpringerLink

duodenal lymphoma anaplastic large cell lymphoma immunohistochemistry Ki-1 positive CD30 antigen extranodal lymphoma ... Pearson JM, Borg-Grech A: Primary Ki-1 (CD30)-positive, large cell, anaplastic lymphoma of the esophagus. Cancer 68:418-421, ... Primary CD30 (Ki-1)-positive anaplastic large cell lymphoma of the duodenum. ... Ross CW, Hanson CA, Schnitzer B: CD30 (Ki-1)-positive, anaplastic large cell lymphoma mimicking gastrointestinal carcinoma. ...
more infohttps://link.springer.com/article/10.1007/BF02100125

MUC1 (EMA) is preferentially expressed by ALK positive anaplastic large cell lymphoma, in the normally glycosylated or only...MUC1 (EMA) is preferentially expressed by ALK positive anaplastic large cell lymphoma, in the normally glycosylated or only...

... and classic HD were all CD30 positive. Two cases of DLBCL showed CD30 expression in a subset of the tumour cells. ALK ... Surface differentiation antigens of human mammary epithelial cells carried on the milk fat globule. Proc Natl Acad Sci U S A ... this case also expressed CD30 on tumour cells. Another CD30 positive DLBCL was MUC1 negative. ... Standard immunophenotyping included CD30, ALK, CD15, B cell markers CD20/L26 and CD79A, and T cell markers CD3 and CD45RO/UCHL- ...
more infohttp://jcp.bmj.com/content/54/12/933

Potentials of brentuximab vedotin in the treatment of relapse/refractory cutaneous T-cell lymphomas: literature review and...Potentials of brentuximab vedotin in the treatment of relapse/refractory cutaneous T-cell lymphomas: literature review and...

More than 75 % of primary cutaneous CD30-positive lymphoma cells express CD30; it may be detected in other diseases as well, ... Activation antigen СD30 is a cell membrane glycoprotein of the tumour necrosis factor family. ... Phase II investigator-initiated study of brentuximab vedotin in mycosis fungoides and Sezary syndrome with variable CD30 ... One of these agents is brentuximab vedotin, a CD30-monoclonal antibody conjugated to monomethyl auristatin E. ...
more infohttps://www.vestnikdv.ru/jour/article/view/482

Anti CD30 CAR - Anti CD30 chimeric antigen receptor selectively targets tumor cellsAnti CD30 CAR - Anti CD30 chimeric antigen receptor selectively targets tumor cells

The invention describes a CAR which recognizes CD30 as a target antigen and initiates lysis of CD30-positive (CD30+) tumor ... Anti CD30 CAR - Anti CD30 chimeric antigen receptor selectively targets tumor cells. 02.09.2015 ... In vivo experiments provided evidence that the treatment with anti-CD30 T-cells has no unwanted impact on the endogenous immune ... Specific genetic modifications of the anti-CD30 CAR ensure the specific targeting of CD30+ tumor cells and prevent unwanted ...
more infohttp://www.innovations-report.com/html/reports/technology-offerings/anti-cd30-car-anti-cd30-chimeric-antigen-receptor-selectively-targets-tumor-cells.html

Antigens, CD30 | Profiles RNSAntigens, CD30 | Profiles RNS

Overexpression of CD30 antigen in hematopoietic malignancies make the antigen clinically useful as a biological tumor marker. ... CD30" by people in this website by year, and whether "Antigens, CD30" was a major or minor topic of these publications. ... "Antigens, CD30" is a descriptor in the National Library of Medicines controlled vocabulary thesaurus, MeSH (Medical Subject ... Below are the most recent publications written about "Antigens, CD30" by people in Profiles. ...
more infohttp://profiles.wakehealth.edu/display/102742

JoVE Search Results: CD30 AntigensJoVE Search Results: CD30 Antigens

Antigen, Cd30 Antigen, Hodgkins Lymphoma, Lymphoma, Chemotherapy, History, Hodgkin Lymphoma, Natural History, Apoptosis, Cell, ... Expression of CD30 in patients with acute graft-versus-host disease. < .001. There were similar levels of CD30 expression in ... CD30 ligand/CD30 plays a critical role in Th17 differentiation in mice. Abstract ... These results suggest that CD30 expression on CD8(+) T-cell subsets or plasma levels of soluble CD30 may be a potential ...
more infohttp://labindex.jove.com/group/CD30-Antigens

T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a...T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a...

C) Killing of CD30+ (HDLM-2, ; Karpas, ■) and CD30− (□) tumor cells by CAR-CD30+ and CCR4+CD30-CAR+ T cells. (D) The ... Furthermore, T lymphocytes expressing both CCR4 and a chimeric antigen receptor directed to the HL associated antigen CD30 ... Improved migration of activated T lymphocytes genetically modified to overexpress CCR4 and a CAR targeting the CD30 antigen ... C) The fold change of bioluminescence signal between K/wt and K/TARC site for CAR-CD30+ (□) and CCR4+CAR-CD30+ (■) T cells. ...
more infohttps://www.ncbi.nlm.nih.gov/pubmed/19377047

CD30 antigen, a marker for Hodgkins lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology...CD30 antigen, a marker for Hodgkin's lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology...

CD30 antigen, a marker for Hodgkins lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology ... CD30 antigen, a marker for Hodgkins lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology ... Sequence homology to members of the tumor necrosis factor (TNF) receptor super family can be observed in CD30, which is a ... cognate from the murine T cell clone 7B9 was expression cloned by using a chimeric probe with the extracellular region of CD30 ...
more infohttp://www.readabstracts.com/Biological-sciences/CD30-antigen-a-marker-for-Hodgkins-lymphoma-is-a-receptor-whose-ligand-defines-an-emerging-family-of.html

JCI -
Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytesJCI - Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes

Targeting CD30 with T cells expressing a CD30-specific chimeric antigen receptor (CAR) may reduce the side effects and augment ... CD30.CAR-T expansion in peripheral blood peaked 1 week after infusion, and CD30.CAR-Ts remained detectable for over 6 weeks. ... Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes. ... Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes. ...
more infohttps://j8k9.com.www.mobile.jci.org/articles/view/94306/pdf

JCI -
Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytesJCI - Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes

Targeting CD30 with T cells expressing a CD30-specific chimeric antigen receptor (CAR) may reduce the side effects and augment ... for CD30. No chemotherapy was given to patients immediately before or after infusion of CD30.CAR-transduced T cells (CD30.CAR- ... Soluble CD30 (sCD30) is typically elevated in advanced HL (30). Although CD30.CAR-Ts are not blocked by sCD30 (26, 31), we ... In our study, CD30.CAR-Ts were well tolerated, and CRs were observed at the highest dose of CD30.CAR-Ts and after 2 or more T ...
more infohttps://6jgc.com.www.mobile.jci.org/articles/view/94306

JCI -
Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytesJCI - Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes

Targeting CD30 with T cells expressing a CD30-specific chimeric antigen receptor (CAR) may reduce the side effects and augment ... for CD30. No chemotherapy was given to patients immediately before or after infusion of CD30.CAR-transduced T cells (CD30.CAR- ... Soluble CD30 (sCD30) is typically elevated in advanced HL (30). Although CD30.CAR-Ts are not blocked by sCD30 (26, 31), we ... In our study, CD30.CAR-Ts were well tolerated, and CRs were observed at the highest dose of CD30.CAR-Ts and after 2 or more T ...
more infohttps://guccidea.com.mobile.jci.org/articles/view/94306

TNFRSF8 Gene - GeneCards | TNR8 Protein | TNR8 AntibodyTNFRSF8 Gene - GeneCards | TNR8 Protein | TNR8 Antibody

Altered expression of the lymphocyte activation antigen CD30 in active celiac disease. (PMID: 20166880) Periolo N … Cherñavsky ... Suggested Antigen Peptide Sequences for TNFRSF8 Gene. GenScript: Design optimal peptide antigens:. *TNFRSF8 protein (A5D8T4_ ... Association study between CD30 and CD30 ligand genes and type 1 diabetes in the Japanese population. (PMID: 11960307) Ahmed S ... tumor necrosis factor receptor superfamily,member 8,cell differentiation antigen CD30 (Ki-1),lymphoid activating,identified by ...
more infohttp://www.genecards.org/cgi-bin/carddisp.pl?gene=TNFRSF8&origene_full_trans=4

Anti-Human CD30 F(ab) Stable Cell Line-CHO CSC-P0126 - Creative BioMartAnti-Human CD30 F(ab) Stable Cell Line-CHO CSC-P0126 - Creative BioMart

... which has been transfected with an anti-human CD30 F(ab) gene to allow expression of the F(ab). It is an example of a cell line ... CHO-Anti-Human CD30 F(ab) stable cell line is clonally-derived from a CHO cell line, ... CD30 antigen; CD30L receptor; Cytokine receptor CD30; D1S166E; KI 1; Ki-1 antigen; KI1; Lymphocyte activation; antigen CD30; ... Anti-Human CD30 F(ab) Stable Cell Line-CHO. Download Datasheet See All TNFRSF8 Products. Bring this labeled protein directly to ...
more infohttps://www.creativebiomart.net/description_145166_309.htm

Recombinant Human CD30 protein (Fc Chimera) (ab220597) | AbcamRecombinant Human CD30 protein (Fc Chimera) (ab220597) | Abcam

Recombinant Human CD30 protein (Fc Chimera) is a HEK 293 Protein fragment 19 to 379 aa range, , 95% purity, , 1.000 Eu/µg ... KI 1 antigen. *Ki-1 antigen. *KI1. *Lymphocyte activation antigen CD30. *TNFRSF 8 ... Recombinant Human CD30 protein (Fc Chimera). See all CD30 proteins and peptides. ... Immobilized Human CD30 Ligand, Mouse IgG2a Fc Tag, at 2 μg/mL (100 μL/well) can bind ab220597 with a linear range of 0.5-31 ng/ ...
more infohttps://www.abcam.com/recombinant-human-cd30-protein-fc-chimera-ab220597.html

A Brentuximab Vedotin Trial for Patients Who Have Previously Participated in a Brentuximab Vedotin Study - Full Text View -...A Brentuximab Vedotin Trial for Patients Who Have Previously Participated in a Brentuximab Vedotin Study - Full Text View -...

Antigens, CD30. Drug Therapy. Hematologic Diseases. Immunotherapy. Monomethylauristatin E. Additional relevant MeSH terms: ... CD30-positive hematologic malignancy.. *At a minimum, experienced clinical benefit in the prior brentuximab vedotin study. For ... Treatment With SGN-35 in Patients With CD30-positive Hematologic Malignancies Who Have Previously Participated in an SGN-35 ... Retreatment arm: Patients with CD30-positive hematologic malignancies who experienced a complete remission (CR) or partial ...
more infohttps://clinicaltrials.gov/ct2/show/NCT00947856

A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin Lymphoma - Full Text View -...A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin Lymphoma - Full Text View -...

Antigens, CD30. Antibody-Drug Conjugate. Antibodies, Monoclonal. Immunotherapy. Autologous stem cell transplant. ...
more infohttps://www.clinicaltrials.gov/ct2/show/NCT02572167

Influence of immunosuppressive drugs on the CD30 molecule in kidney transplanted patients.Influence of immunosuppressive drugs on the CD30 molecule in kidney transplanted patients.

Soluble CD30 (sCD30) is a suggested marker for kidney transplantation outcomes. We investigated whether sCD30 serum levels are ... Overexpression of CD30 antigen in hematopoietic malignancies make the antigen clinically useful as a biological tumor marker. ... Antigens, Cd30. A member of the tumor necrosis factor receptor superfamily that may play a role in the regulation of NF-KAPPA B ... Summary of "Influence of immunosuppressive drugs on the CD30 molecule in kidney transplanted patients.". Soluble CD30 (sCD30) ...
more infohttps://www.bioportfolio.com/resources/pmarticle/2020345/Influence-of-immunosuppressive-drugs-on-the-CD30-molecule-in-kidney-transplanted-patients.html

Primary cutaneous CD30+ large T-cell lymphoma in a patient with psoriasis treated with cyclosporine.Primary cutaneous CD30+ large T-cell lymphoma in a patient with psoriasis treated with cyclosporine.

Antigens, CD30 / blood*. Cyclosporine / adverse effects*, therapeutic use. Etretinate / therapeutic use. Fatal Outcome. Female ... 0/Antigens, CD30; 0/Immunosuppressive Agents; 0/Keratolytic Agents; 0/Tumor Markers, Biological; 54350-48-0/Etretinate; 59865- ...
more infohttp://www.biomedsearch.com/nih/Primary-cutaneous-CD30-large-T/12771475.html

Recombinant Human TNFRSF8 protein, Fc-tagged, APC labeled TNFRSF8-1594HA - Creative BioMartRecombinant Human TNFRSF8 protein, Fc-tagged, APC labeled TNFRSF8-1594HA - Creative BioMart

Ki-1 antigen; CD30L receptor; cytokine receptor CD30; lymphocyte activation antigen CD30; CD30; Ki-1; D1S166E;. ... TNFRSF8; tumor necrosis factor receptor superfamily, member 8; CD30, D1S166E; tumor necrosis factor receptor superfamily member ...
more infohttps://www.creativebiomart.net/recombinant-human-tnfrsf8-protein-fc-tagged-apc-labeled-503321.htm

Frontiers | Cellular Cholesterol Distribution Influences Proteolytic Release of the LRP-1 Ectodomain | PharmacologyFrontiers | Cellular Cholesterol Distribution Influences Proteolytic Release of the LRP-1 Ectodomain | Pharmacology

... and CD30 antigen (von Tresckow et al., 2004). By comparing two cell lines exhibiting different levels of cholesterol ( ... 2004). Depletion of cellular cholesterol and lipid rafts increases shedding of CD30. J. Immunol. 172, 4324-4331. doi: 10.4049/ ...
more infohttps://www.frontiersin.org/articles/10.3389/fphar.2016.00025/full

Immunoblastic lymphomaImmunoblastic lymphoma

The CD30 antigen is negative. CD5 is positive in 10% of the cases. CD10 is expressed in approximately half of the cases. ...
more infohttp://atlasgeneticsoncology.org/Anomalies/ImmunoLymphoID2092.html

Severe Acute Pulmonary Toxicity Associated with Brentuximab in a Patient with Refractory Hodgkins LymphomaSevere Acute Pulmonary Toxicity Associated with Brentuximab in a Patient with Refractory Hodgkin's Lymphoma

... and an anti-CD30 monoclonal antibody [4]. Brentuximab binds and is internalized by cells that express the CD30 antigen; ... The CD30 antigen is significantly present in the tumors of Hodgkin lymphoma and anaplastic large cell lymphoma; as such this ... A. M. Newland, J. X. Li, L. E. Wasco, M. T. Aziz, and D. K. Lowe, "Brentuximab vedotin: a CD30-Directed antibody-cytotoxic drug ... N. M. Okeley, J. B. Miyamoto, X. Zhang et al., "Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate ...
more infohttps://www.hindawi.com/journals/cripu/2016/2359437/

cleaved cell lymphoma drug therapy 2000:2010[pubdate] *count=100 - BioMedLib™ search enginecleaved cell lymphoma drug therapy 2000:2010[pubdate] *count=100 - BioMedLib™ search engine

MeSH-minor] Antigens, CD / pharmacology. Apoptosis. CD30 Ligand. CD40 Ligand / pharmacology. Carrier Proteins / pharmacology. ... Such constitutive CD30 cleavage is enhanced after binding of most anti-CD30 antibodies, leading to a downregulation of CD30 and ... Chemical-registry-number] 0 / Antigens, CD; 0 / CD30 Ligand; 0 / Carrier Proteins; 0 / Chromones; 0 / Membrane Glycoproteins; 0 ... Chemical-registry-number] 0 / Aminopyridines; 0 / Antibodies, Monoclonal; 0 / Antigens, CD30; 0 / BB 3644; 0 / Hydroxamic Acids ...
more infohttp://www.bmlsearch.com/?kwr=cleaved+cell+lymphoma+drug+therapy+2000:2010%5Bpubdate%5D&cxts=100&stmp=b1
  • It may be nonspecific as in the administration of immunosuppressive agents (drugs or radiation) or by lymphocyte depletion or may be specific as in desensitization or the simultaneous administration of antigen and immunosuppressive drugs. (bioportfolio.com)
  • Immobilized Human CD30 Ligand, Mouse IgG2a Fc Tag, at 5 μg/mL (100 μL/well) can bind ab220597 with a linear range of 8-125 ng/mL. (abcam.com)
  • It is expressed mainly on activated CD4+ and CD8+ T cells, and binds to a high-affinity ligand (4-1BBL) expressed on several antigen-presenting cells such as macrophages and activated B cells. (creative-biolabs.com)
  • This approach is intended to spare non-targeted cells and thus may help minimize the potential toxic effects of traditional chemotherapy while allowing for the selective targeting of CD30-expressing cancer cells, thus potentially enhancing the antitumor activity. (drugs.com)
  • Reports in 2013 showed interim results from a Phase II, open-label, single-arm study designed to evaluate the antitumor activity of brentuximab vedotin in relapsed or refractory CD30-positive NHL, including B-cell neoplasms. (wikipedia.org)
  • We conducted a phase I dose escalation study in which 9 patients with relapsed/refractory HL or ALCL were infused with autologous T cells that were gene-modified with a retroviral vector to express the CD30-specific CAR (CD30.CAR-Ts) encoding the CD28 costimulatory endodomain. (jci.org)
  • Expression of the costimulatory receptor CD30 is regulated by both CD28 and cytokines. (semanticscholar.org)
  • The antibody cAC10 part of the drug binds to CD30 which often occurs on diseased cells but rarely on normal tissues.The antibody portion of the drug attaches to CD30 on the surface of malignant cells, delivering MMAE which is responsible for the anti-tumour activity. (wikipedia.org)
  • The zeta chain plays an important role in coupling antigen recognition to several intracellular signal-transduction pathways. (creative-biolabs.com)
  • Influence of immunosuppressive drugs on the CD30 molecule in kidney transplanted patients. (bioportfolio.com)
  • Specific genetic modifications of the anti-CD30 CAR ensure the specific targeting of CD30+ tumor cells and prevent unwanted side-effects. (innovations-report.com)
  • In vivo experiments provided evidence that the treatment with anti-CD30 T-cells has no unwanted impact on the endogenous immune system. (innovations-report.com)
  • Although CD30 may also be expressed by normal activated T cells, no patients developed impaired virus-specific immunity. (jci.org)
  • The ADC employs a linker system that is designed to be stable in the bloodstream but to release MMAE upon internalization into CD30-expressing tumor cells. (drugs.com)
  • Of 7 patients with relapsed HL, 1 entered complete response (CR) lasting more than 2.5 years after the second infusion of CD30.CAR-Ts, 1 remained in continued CR for almost 2 years, and 3 had transient stable disease. (jci.org)
  • Of 2 patients with ALCL, 1 had a CR that persisted 9 months after the fourth infusion of CD30.CAR-Ts. (jci.org)
  • CD30.CAR-Ts are safe and can lead to clinical responses in patients with HL and ALCL, indicating that further assessment of this therapy is warranted. (jci.org)
  • CD30.CAR-T expansion in peripheral blood peaked 1 week after infusion, and CD30.CAR-Ts remained detectable for over 6 weeks. (jci.org)
  • CD30 is up-regulated in several human diseases and viral infections but its role in immune regulation is poorly understood. (semanticscholar.org)
  • This graph shows the total number of publications written about "Antigens, CD30" by people in this website by year, and whether "Antigens, CD30" was a major or minor topic of these publications. (wakehealth.edu)